document incorporate reference specify portion registrant proxy statement file commission pursuant regulation connection registrant annual meeting stockholder hold incorporate reference iii report base closing price share june exclude share registrant common stock hold executive officer director stockholder ownership exceed registrant common stock outstanding june exclusion share construe indicate person possess power direct indirect direct cause direction management policy registrant person control common control registrantgilead sciences inc annual report table content item business item risk factor item b unresolved staff comment item property item legal proceeding item safety disclosure ii item market registrant common equity relate stockholder matter issuer purchase equity security item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum item change disagreement accountant account financial disclosure item control procedure item b information iii item director executive officer corporate governance item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction director independence item principal accountant fee service iv item exhibit financial statement schedule signature right trademark copyright trade name business include follow gilead gilead sciences ambisome cayston complera emtriva eviplera genvoya harvoni hepsera letairis ranexa rapiscan sovaldi stribild truvada tybost viread vitekta volibris zydelig atripla register trademark belong bristolmyer squibb gilead sciences llc lexiscan register trademark belong astella llc macugen register trademark belong eyetech inc sustiva register trademark bristolmyers squibb pharma company tamiflu register trademark belong hoffmannla roche inc report include trademark service mark trade name companiesthis annual report include section entitle management discussion analysis financial condition result operation contain forwardlooke statement future event future result subject safe harbor create security act amend securities act securities exchange act amended exchange act word expect anticipate target goal project hope intend plan believe seek estimate continue variation word similar expression intend identify forwardlooke statement addition statement statement historical fact forward look statement include statement overall trend operate cost revenue trend liquidity capital need statement expectation belief future plan strategy anticipate event trend similar expression base forwardlooke statement current expectation future event statement guarantee future performance involve risk uncertainty assumption difficult predict actual result differ materially suggest forwardlooke statement reason include identify item head risk factor give risk uncertainty caution place undue reliance forwardlooke statement forwardlooke statement include report date hereof require federal security law rule regulation securities exchange commission sec undertake specifically decline obligation update statement publicly announce result revision forwardlooke statement distribution report result new information future event change assumption item business overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world gilead primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis c virus hcv infection chronic hepatitis b virus hbv infection cardiovascular hematologyoncology inflammationrespiratory operation country worldwide headquarters foster city california continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy highlight past year worked bring bestinclass drug market advance standard care offering enhance mode delivery convenient treatment regimen improve resistance profile reduce effect great efficacy hiv area receive approval food drug administration fda european commission genvoya elvitegravir mgcobicistat mgemtricitabine mgtenofovir alafenamide mg ecftaf oncedaily single tablet regimen treatment hiv infection tafbase regimen currently evaluation fda european medicine agency ema investigational fixeddose combination emtricitabine mg tenofovir alafenamide mg ftaf use combination antiretroviral agent second investigational oncedaily single tablet regimen combine emtricitabine mg tenofovir alafenamide mg rilpivirine mg rftaf liver disease area receive approval fda expand use harvoni patient genotype chronic hcv infection patient coinfecte hiv addition harvoni plus ribavirin rbv week approve alternate therapy week harvoni treatmentexperience genotype patient cirrhosis submit marketing application fda ema approval oncedaily fixeddose combination sofosbuvir sof approve sovaldi december velpatasvir vel investigational pan genotypic nsa inhibitor treatment chronic genotype hcv approve sofvel pangenotypic alloral single tablet regimen treatment hcv complement current hcv portfolio sovaldi harvoni offer high cure rate potential simplify treatment eliminate need hcv genotype testing hematologyoncology area submit supplemental new drug application fda ema approval zydelig idelalisib combination ofatumumab previouslytreate patient chronic lymphocytic leukemia cll zydelig originally approve combination rituximab treatment certain patient cll small lymphocytic lymphoma follicular lymphoma common type indolent nonhodgkin lymphoma inhl advanced research development pipeline active clinical study end phase clinical trial addition advance treatment option therapeutic area enable access medication people need world expand generic licensing agreement indiabase manufacturing partner include sofvel approve distribution develop country pangenotypic therapeutic option treatment hcv particularly important develop country genotype testing unreliable readily available expand geographic scope licensing agreement indiabase manufacturing partner include develop country update tiere pricing strategy brand hcv medicine available significantly reduce publicgovernment price country make pricing country clear transparent hope facilitate planning encourage meaningful public health response hcv hiv program goal ensure hiv patient choose single tablet regiman right single tablet regimen allow patient adhere fully suppressive course therapy easily consistently critical successful management disease hiv patient live long face additional health challenge experience newly diagnose patient motivate continue improve exist treatment option need efficacy improve longterm safety drive development program design study complete planned look forward introduce new generation taf single tablet regimen create address evolve need people live hiv taf novel target prodrug tenofovir demonstrate high antiviral efficacy similar dose onetenth viread tenofovir disoproxil fumarate tdf improvement surrogate laboratory marker renal bone safety compare clinical trial tdf combination antiretroviral agent launch tafbase regimen genvoya single tablet regimen available treatment hiv marketing approval additional tafbase product candidate ftaf rftaf pende united states european union product candidate rftaf assign approval date prescription drug user fee act pdufa march european commission decision expect quarter ftaf assign pdufa date april european commission decision expect second quarter emtricitabine taf gilead rilpivirine janssen sciences ireland uc janssen addition investigate additional tafbase single tablet regimen taf emtricitabine gs proprietary integrase inhibitor currently phase clinical study taf emtricitabine cobicistat janssen darunavir dcftaf develop commercialize janssen liver disease goal advance treatment option standard care underserve hcv market approval sovaldi compare prior standard care week duration treatment shorten week need peginterferon pegifn injection certain viral genotype population reduce eliminate completely receive fda european commission approval harvoni oncedaily single tablet regimen treatment hcv genotype infect patient prevalent genotype united states receive approval harvoni japan harvoni combine nsa inhibitor ledipasvir sofosbuvir indicate week treatment duration depend prior treatment history cirrhosis status baseline viral load eliminate need pegifn rbv challenge tolerate fda expand use harvoni include patient genotype chronic hcv infection patient coinfecte hiv addition harvoni plus ribavirin week approve alternate therapy week harvoni treatmentexperience genotype patient cirrhosis long term goal develop oral therapy hcv patient genotype fourth quarter submit marketing application fda ema approval oncedaily fixeddose combination sofvel treatment chronic genotype hcv fourth quarter initiate phase clinical trial evaluate oncedaily fixeddose combination sof vel gs investigational ns protease inhibitor treatment chronic genotype hcv evaluate taf treatment chronic hbv infection base datum phase clinical trial file marketing application fda ema quarter conduct phase clinical trial gs oral tlr agonist gs tarmogen cell immunity stimulator treatment hbv evaluate simtuzumab monoclonal antibody treatment nonalcoholic steatohepatitis nash primary sclerose cholangitis phase clinical trial evaluate gs ask inhibitor nash phase clinical trial evaluate gs fxr agonist nash phase clinical trial cardiovascular receive fda approval use letairis ambrisentan combination tadalafil treatment pulmonary arterial hypertension pah group reduce risk disease progression hospitalization worsen pah improve exercise ability letairis endothelin receptor antagonist approve united states monotherapy pah improve exercise ability delay clinical worsen tadalafil pde inhibitor initially approve pah united states improve exercise ability eleclazine know gs late sodium channel inhibitor evaluate phase clinical trial treatment long qt syndrome eleclazine evaluate phase clinical trial treatment hypertrophic cardiomyopathy ventricular tachycardiaventricular fibrillation evaluate gs ask inhibitor pulmonary arterial hypertension phase clinical trial hematologyoncology oncology area seek expand use zydelig idelalisib firstinclass pik delta inhibitor treatment patient certain blood cancer submit supplemental new drug application fda ema approval zydelig combination ofatumumab previously treat patient cll idelalisib phase clinical trial treatment patient frontline relapse refractory cll relapse refractory inhl plan submit supplemental regulatory filing fda ema approval zydelig combination bendamustine rituximab patient previously treat cll second quarter fourth quarter initiate phase clinical trial evaluate gs mmp mab inhibitor treatment gastric cancer conduct phase clinical trial evaluate momelotinib treatment myleofibrosis pancreatic cancer inflammationrespiratory inflammationrespiratory area advance product candidate clinical trial presatovir know gs fusion inhibitor currently phase clinical trial treatment respiratory syncytial virus gs mmp mab inhibitor evaluate phase clinical trial ulcerative colitis crohns disease filgotinib jak inhibitor evaluate phase clinical trial rheumatoid arthritis crohn disease product hiv genvoya oral formulation dose day treatment hiv infection adult genvoya fourth complete single tablet regimen treatment hiv fixeddose combination antiretroviral medicine vitekta elvitegravir mg mg tybost cobicistat emtriva emtricitabine taf mg genvoya approve fda european commission november stribild oral formulation dose day treatment hiv infection treatmentnaive adult stribild complete single tablet regimen treatment hiv fixeddose combination antiretroviral medication vitekta tybost viread emtriva compleraeviplera oral formulation dose day treatment hiv infection adult product market united states complera europe eviplera second complete single tablet regimen treatment hiv fixeddose combination antiretroviral medication viread emtriva janssen nonnucleoside reverse transcriptase inhibitor edurant rilpivirine atripla oral formulation dose day treatment hiv infection adult atripla single tablet regimen hiv intend standalone therapy combination antiretroviral fixeddose combination antiretroviral medication viread emtriva bristolmyers squibb company bms nonnucleoside reverse transcriptase inhibitor sustiva efavirenz truvada emtricitabine tenofovir disoproxil fumarate oral formulation dose day combination therapy treat hiv infection adult fixeddose combination antiretroviral medication viread emtriva fda approve truvada combination safe sex practice reduce risk sexually acquire hiv infection adult high risk strategy call preexposure prophylaxis prep viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection patient year age old european commission approve use viread combination antiretroviral agent treatment hiv infect adolescent patient age year nucleoside reverse transcriptase inhibitor resistance toxicity precluding use firstline pediatric agent viread approve treatment chronic hbv emtriva oral formulation nucleoside analog reverse transcriptase inhibitor dose day combination therapy treat hiv infection adult united states europe emtriva available oral solution approve combination therapy treat hiv infection child tybost pharmacokinetic enhancer dose day boost blood level certain hiv medicine tybost indicate boost agent hiv protease inhibitor atazanavir darunavir antiretroviral combination therapy adult hiv infection vitekta oral formulation integrase inhibitor dose day combination therapy treat hiv infection adult know mutation associate resistance elvitegravir active ingredient vitekta vitekta indicate use hiv treatment regimen include ritonavirbooste protease inhibitor liver disease harvoni oral formulation nsa inhibitor nucleotide analog polymerase inhibitor dose day treatment genotype hcvhiv coinfection hcv genotype liver transplant recipient genotype infect patient decompensate cirrhosis europe harvoni indicate certain patient hcv genotype infection hcv genotype infection cirrhosis andor prior treatment failure hcvhiv coinfection sovaldi oral formulation nucleotide analog polymerase inhibitor dose day treatment hcv component combination antiviral treatment regimen sovaldi efficacy establish patient hcv genotype infection united states europe genotype infection europe include hepatocellular carcinoma meeting milan criterion await liver transplantation hcvhiv coinfection viread oral formulation nucleotide analog reverse transcriptase inhibitor dose day treatment chronic hbv adult compensate decompensate liver disease license glaxosmithkline inc gsk right commercialize viread treatment chronic hbv china japan saudi arabia european commission approve use viread treatment chronic hbv infection adolescent patient age year compensate liver disease evidence immune active disease viread approve treatment hiv infection hepsera adefovir dipivoxil oral formulation nucleotide analog polymerase inhibitor dose day treat chronic hbv patient year age old license gsk right commercialize hepsera treatment chronic hbv asia pacific latin america certain territory cardiovascular letairis ambrisentan oral formulation endothelin receptor antagonist era indicate treatment pulmonary arterial hypertension pah world health organization group patients class ii iii symptom improve exercise capacity delay clinical worsen sublicense gsk right ambrisentan market gsk volibris ambrisentan pah territory outside united states ranexa ranolazine extendedrelease tablet treatment chronic angina licensed menarini international operation luxembourg sa rights ranexa territory outside united states lexiscanrapiscan regadenoson injection indicate use pharmacologic stress agent radionuclide myocardial perfusion image mpi test detect characterize coronary artery disease patient unable undergo adequate exercise stress astella llc astella exclusive right manufacture sell regadenoson lexiscan united states rapidscan pharma solutions inc rps hold exclusive right manufacture sell regadenoson rapiscan europe certain territory outside united states receive royalty astella rps sale territory hematologyoncology zydelig firstinclass pik delta inhibitor treatment certain blood cancer united states zydelig approve combination rituximab patient relapse chronic lymphocytic leukemia cll rituximab consider appropriate therapy monotherapy patient relapse follicular bcell nonhodgkin lymphoma fl small lymphocytic lymphoma sll receive prior systemic therapy european union zydelig approve treatment cll fl inflammationrespiratory cayston aztreonam inhalation solution inhale antibiotic treatment respiratory system cystic fibrosis cf patient seven year age old pseudomona aeruginosa p aeruginosa tamiflu oseltamivir phosphate oral antiviral available capsule form treatment prevention influenza b tamiflu approve treatment influenza child adult country include united states japan european union tamiflu approve prevention influenza child adults united states japan european union develop tamiflu f hoffmannla roche ltd hoffmannla roche inc roche roche exclusive right manufacture sell tamiflu worldwide subject obligation pay royalty base percentage net sale tamiflu ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treat invasive fungal infection cause fungal specie adult corporate partner astella pharma inc promote sell ambisome united states canada promote sell ambisome europe australia new zealand macugen pegaptanib sodium injection intravitreal injection antiangiogenic oligonucleotide treatment neovascular agerelate macular degeneration macugen develop eyetech inc eyetech technology license promote united states valeant pharmaceuticals inc valeant acquire eyetech valeant hold exclusive right manufacture sell macugen united states pfizer inc pfizer hold exclusive right manufacture sell macugen rest world receive royalty valeant pfizer base worldwide sale macugen sale antiviral product include product hiv liver disease area describe billion billion billion represent total revenue total revenue total revenue sale product billion billion billion represent total revenue total revenue total revenue item management discussion analysis item note segment information consolidate financial statement include annual report information relate sale product commercialization distribution international commercial sale operation marketing subsidiary country product market commercial team andor conjunction thirdparty distributor corporate partner commercial team promote product direct field contact physician hospital clinic healthcare provider generally grant thirdparty distributor exclusive right promote product territory specify period time agreement distributor provide collaborative effort distributor gilead obtain maintain regulatory approval product specify territory sell distribute harvoni sovaldi truvada atripla stribild complera viread genvoya emtriva tybost vitekta ranexa ambisome zydelig hepsera united states exclusively wholesale channel product sale large wholesaler cardinal health inc mckesson corporation amerisourcebergen corporation account total revenue year end december combine basis wholesaler account approximately product sale united states approximately total worldwide revenue letairis cayston distribute exclusively specialty pharmacy specialty pharmacy dispense medication complex chronic condition require high level patient education ongoing counseling sell distribute harvoni sovaldi truvada atripla stribild eviplera viread emtriva tybost vitekta genvoya ranexa ambisome zydelig hepsera europe country outside united states product approve commercial team thirdparty distributor corporate partner patient access priority increase access medicine people benefit regardless ability pay united states patient assistance program help therapy accessible uninsured individual need financial assistance support program unable afford copayment associate health insurance program half patient take hiv medicine united states receive federal state program substantially discount price long history work state aids drug assistance program adap provide low pricing hiv medicine price freeze institute adap extend end provide important support critical program evolve change healthcare environment access develop world gilead access program establish certain product hivaid viral hepatitis visceral leishmaniasis available substantially reduce price develop world work network regional business partner generic licensing partner medicine patent pool stakeholder expand treatment globally enter number collaboration relate access product develop world include license generic manufacturer enter nonexclusive license agreement indian generic manufacturer grant right produce distribute generic version tdf emtricitabine cobicistat elvitegravir include generic version combination product contain cobicistat elvitegravir tdf emtricitabine treatment hiv infection low income country world include india country gilead access program include nonexclusive license agreement ability manufacture distribute generic version tdf treatment hbv country authorize sell generic version tdf hiv grant certain indian partner direct license produce distribute generic taf develop world include single tablet regimen contain emtricitabine fixeddose combination taf emtricitabine coformulate hiv medicine enter collaboration indian partner produce distribute generic version lowincome country lowermiddle income country early expand collaboration allow indian partner manufacture vel single tablet regimen sofvel approve medicine patent pool mpp enter agreement mpp organization establish united nations increase global access highquality lowcost antiretroviral therapy sharing patent grant mpp nonexclusive license identify generic pharmaceutical manufacturer india specialize highquality production generic medicine grant sublicense indian manufacturer manufacture distribute generic version antiretroviral develop world sublicensee mpp free develop combination product pediatric formulation hiv medicine grant mpp right grant sublicense generic version elvitegravir cobicistat single tablet regimen consist elvitegravir cobicistat tdf emtricitabine taf hiv hbv develop country contingent medicine regulatory approval special partnership work national government local organization increase access hiv hcv medicine strengthen healthcare system example establish agreement national aids program myanmar donate generic version atripla people live hiv country provide hiv educational activity financial support strengthen countrys health system tanzania launch hiv testandtreat demonstration project holy see good samaritan foundation program goal enable screen patient hiv provide hiv therapy hivpositive individual year egypt agree provide sovaldi harvoni egyptian ministry health significantly reduce price addition partnership ministry health invest local hcv medical education prevention effort screen patient awareness initiative georgia establish agreement ministry labor health social affair georgia help eliminate hcv country project aim reduce number georgian infect hcv low rate new infection universal screen treatment prevention surveillance competition market product target number area include hiv liver disease hematologyoncology cardiovascular inflammationrespiratory disease commercially available product treatment disease face significant competition large global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer product compete available product base primarily efficacy safety tolerability acceptance doctor ease patient compliance ease use price insurance reimbursement coverage distribution marketing hiv product hiv landscape competitive complex treatment trend continue evolve grow number hiv drug currently sell advanced stage clinical development competition current expect competitor erode revenue receive sale hiv product hiv product compete primarily product viiv healthcare viiv market fixeddose combination product compete genvoya stribild compleraeviplera atripla truvada example product market viiv tivicay dolutegravir integrase inhibitor triumeq dolutegravirabacavirlamivudine single tablet antiretroviral regimen adversely impact sale hiv product addition viiv lamivudine compete emtricitabine active pharmaceutical ingredient emtriva component genvoya stribild compleraeviplera atripla truvada tybost compete ritonavir market abbvie inc abbvie face competition generic hiv product generic version lamivudine combivir lamivudine zidovudine available united states certain country generic version sustiva efavirenz component atripla available canada europe anticipate competition generic efavirenz united states december observe pricing pressure relate sustiva component atripla sale liver disease product hcv product harvoni sovaldi compete viekira pak ombitasvir paritaprevir ritonavir tablet copackage dasabuvir tablet market abbvie zepatier elbasvir grazoprevir market merck co inc merck daklinza daclastavir market bristolmyer squibb company bms olysio simeprevir market janssen therapeutic hbv product viread hepsera face competition exist expect therapy treat patient hbv hbv product face competition baraclude entecavir oral nucleoside analog market bm generic entecavir hbv product compete tyzekasebivo telbivudine oral nucleoside analog market novartis pharmaceutical corporation novartis cardiovascular product letairis competes tracleer bosentan opsumit macitentan market actelion pharmaceutical inc adcirca tadalafil market united therapeutics corporation pfizer inc pfizer ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate addition surgical treatment intervention coronary artery bypass graft percutaneous coronary intervention option angina patient perceive healthcare practitioner prefer method treat cardiovascular disease underlie cause angina numerous market generic andor brand pharmacologic stress agent compete lexiscanrapiscan hematologyoncology product zydelig competes imbruvica ibrutinib market pharmacyclics inc gazyva obinutuzumab market genentech member roche group treanda bendamustine hydrochloride market cephalon inc inflammationrespiratory product cayston compete primarily tobi tobramycin inhalation solution inhale medication market novartis treatment cystic fibrosis patient lung contain p aeruginosa bacterial infection tamiflu competes relenza zanamivir influenza neuraminidase inhibitor market glaxosmithkline product sell generic competitor product ambisome compete vfend voriconazole market pfizer caspofungin product develop merck market cancidas united states caspofungin ambisome compete lipidbase amphotericin b product include abelcet amphotericin b lipid complex injection sell enzon pharmaceuticals inc united states canada japan zeneus pharma ltd europe amphotec amphotericin b cholesteryl sulfate complex injection sell river pharmaceutical llc worldwide anfogen amphotericin b liposomal sell genpharma sa argentina bms numerous generic manufacturer sell conventional amphotericin b compete ambisome addition aware lipid formulation claim similarity ambisome available outside united states formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share product adversely affect result operation stock price collaborative relationship business strategy establish collaboration company university medical research institution assist clinical development andor commercialization certain product product candidate provide support research program evaluate opportunity acquire product right product technology complementary business company university medical research institution information certain relationship include ongoing financial accounting impact business item note collaborative arrangement consolidate financial statement include annual report commercial collaboration currently number collaboration corporate partner manufacture sale distribution andor marketing product territory worldwide follow commercial collaboration significant financial statement perspective significant ongoing collaboration activity exist bms enter collaboration arrangement bms develop commercialize single tablet regimen contain truvada bms sustiva efavirenz united states combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration bms amend joint venture collaboration agreement allow joint venture sell atripla canada economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bms respective economic interest joint venture vary annually bms share marketing sale effort start limited number activity jointly manage party long coordinate detail promotional activity united states party reduce joint promotional effort launch complera august stribild august efavirenz purchase joint venture bms bms estimate net selling price efavirenz include inventory consolidate balance sheet december agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination gilead sciences ireland unlimited company whollyowne subsidiary bms enter collaboration agreement bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bms estimate net selling price efavirenz european territory start limited number activity jointly manage party long coordinate detail promotional activity region efavirenz purchase bms bms estimate net selling price efavirenz european territory include inventory consolidate balance sheet december agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early janssen enter collaboration agreement janssen develop commercialize fixeddose combination truvada janssen rilpivirine agreement amend combination approve united states european union sell brand complera united states eviplera european union amendment expand collaboration include single tablet regimen contain janssen rilpivirine emtricitabine tenofovir alafenamide rftaf agreement janssen grant exclusive license compleraeviplera rftaf worldwide right distribute combination product country include mexico russia japan party restrict combine drug drug product similar component compleraeviplera rftaf responsible manufacturing compleraeviplera rftaf lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country gilead sell party selling party set price product party share revenue base ratio net selling price party component subject certain restriction adjustment retain specify percentage janssen share revenue major market party terminate collaboration agreement respect product country product withdraw market country respect product country party materially breach agreement respect product agreement party obligation share revenue expire productbyproduct countrybycountry basis janssen patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement cause respect country sell product case janssen right sell party country product launch market few year japan tobacco japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort receive approval stribild elvitegravircontaine product fda august european commission receive approval genvoya elvitegravircontaine product fda european commission november agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party research collaboration number collaboration partner research development rd certain compound drug candidate research collaboration significant financial statement perspective research development rd philosophy strategy develop bestinclass drug improve safety efficacy unmet medical need intend continue commit significant resource internal rd opportunity external business development activity product development effort cover wide range medical condition include hivaid liver disease hbv hcv inflammationoncology cardiovascular respiratory condition research scientist foster city fremont san dimas oceanside california seattle washington alberta canada engage discovery development new molecule technology hope lead approval new medicine address unmet need development product candidate subject risk uncertaintie risk uncertainty include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain regulatory approval result product candidate successfully commercialize drug development inherently risky product candidate fail drug development process summary key product candidate correspond current stage development product candidate treatment hiv product candidate description marketing application pende fixeddose coformulation emtricitabine fixeddose coformulation emtricitabine taf evaluate treatment hiv infection taf ftaf single tablet regimen emtricitabine rilpivirine agreement janssen single tablet regimen emtricitabine rilpivirine taf evaluate taf rftaf treatment hiv infection product phase single tablet regimen gs nonbooste single tablet regimen gs ftaf evaluate treatment hiv infection integrase inhibitor ftaf product phase gs gs tlr agonist evaluate treatment hiv infection product candidate treatment liver disease product candidate description market application pende single tablet regimen sofosbuvir sof single tablet regimen sofosbuvir velpatasvir nucleotide nsb inhibitorpangenotypic nsa velpatasvir vel inhibitor evaluate treatment hcv taf taf nucleotide reverse transcriptase inhibitor evaluate treatment hbv product phase single tablet regimen gs sofvel single tablet regimen gs pangenotypic ns protease inhibitor sofvel evaluate treatment hcv product phase gs gs tarmogen cell immunity stimulator evaluate treatment hbv gs gs evaluate treatment hbv simtuzumab simtuzumab monoclonal antibody evaluate treatment nash primary sclerosing cholangitis gs gs ask inhibitor evaluate treatment diabetic nephropathy nash product candidate treatment cardiovascular disease product candidate description product phase eleclazine eleclazine late sodium current inhibitor evaluate treatment long qt syndrome product phase eleclazine eleclazine evaluate treatment hypertrophic cardiomyopathy ventricular tachycardiaventricular fibrillation gs gs evaluate treatment pulmonary arterial hypertension product candidate treatment hematologyoncology product candidate description product phase idelalisib idelalisib pik delta inhibitor evaluate treatment frontline relapse refractory cll relapse refractory inhl momelotinib momelotinib jak inhibitor evaluate treatment myelofibrosis pancreatic cancer gs gs mmp mab inhibitor evaluate treatment gastric cancer product phase entospletinib entospletinib spleen tyrosine kinase syk inhibitor evaluate treatment hematological malignancy idelalisib idelalisib evaluate treatment frontline inhl product phase gs gs bruton tyrosine kinase inhibitor evaluate treatment bcell malignancy gs gs evaluate treatment solid tumor gs gs bromodomain extraterminal bet inhibitor evaluate treatment solid tumor product candidate treatment inflammationrespiratory disease product candidate description product phase filgotinib jakselective inhibitor evaluate treatment rheumatoid arthritis crohn filgotinib disease gs gs evaluate treatment ulcerative colitis crohns disease presatovir presatovir fusion inhibitor evaluate treatment respiratory syncytial virus product phase gs gs evaluate treatment chronic obstructive pulmonary disease rheumatoid arthritis gs gs syk inhibitor evaluate treatment rheumatoid arthritis product candidate product candidate description product phase gs gs evaluate treatment diabetic nephropathy product phase gs gs nucleotide prodrug evaluate treatment ebola total rd expense billion billion billion addition internal discovery clinical development program seek add portfolio product product acquisition license collaboration enter license collaboration agreement galapagos nv galapagos clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor investigate inflammatory disease indication agreement effective january phase trial rheumatoid arthritis crohn disease expect start patent proprietary right european patent expiration number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent follow table show estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent phase product candidate patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve product candidate single tablet regimen estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen phase product candidate patent expiration product candidate treatment hiv eu single tablet regimen emtricitabine taf single tablet regimen darunavir cobicistat emtricitabine taf single tablet regimen emtricitabine rilpivirine taf single tablet regimen gs ftaf product candidate treatment liver disease single tablet regimen sofosbuvir velpatasvir treatment hcv single tablet regimen sofosbuvir velpatasvir gs treatment hcv single agent taf treatment hbv product candidate treatment oncologyinflammation idelalisib treatment frontline relapse refractory cll relapse refractory inhl momelotinib treatment myelofibrosis pancreatic cancer gs treatment gastric cancer product candidate treatment cardiovascular disease eleclazine know gs treatment lqt syndrome date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant follow table show actual estimate expiration date include patent term extension supplementary protection certificate andor pediatric exclusivity grant united states europe primary typically compound patent market product product fix dose combination single tablet regimen eg truvada atripla compleraeviplera stribild genvoya estimate patent expiration date provide correspond late expiring compound patent active ingredient single tablet regimen product patent expiration eu hepsera ambisome macugen tamiflu letairis viread ranexa atripla cayston emtriva truvada lexiscan compleraeviplera vitekta zydelig sovaldi stribild genvoya tybost harvoni date parenthesis reflect estimate expiration date patent issue currently pende application estimate expiration date include potential additional exclusivity eg patent term extension supplementary protection certificate pediatric exclusivity grant gilead teva pharmaceutical teva reach agreement principle settle ongoing patent litigation concern patent protect tenofovir disoproxil fumarate viread truvada atripla product agreement teva allow launch generic version viread december gilead lupin limited lupin reach agreement settle patent litigation prior issuance court decision agreement lupin allow launch generic version ranexa february patent protection certain challenge patent proprietary right important business properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology patent cover certain active pharmaceutical ingredient truvada atripla stribild compleraeviplera genvoya vitekta emtriva letairis hepsera hold party acquire exclusive right patent agreement party patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country example extension patent supplementary protection certificate product grant united states number european country compensate delay obtain marketing approval similar patent term extension available product develop certain obtain country important infringe valid patent party infringe valid patent party prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware body patent relate operation letairis education access program leap restrict distribution program design support letairis aware patent patent application own party claim cover use sofosbuvir use combination sofosbuvir ledipasvir patent application confidential period time patent issue know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate interferencederivation proceeding litigation determine right patent litigation interferencederivation proceeding unpredictable expensive ultimately successful result operation adversely affect event patent relate pharmaceutical biopharmaceutical biotechnology product compound process cover exist compound product process likely file future provide complete adequate protection future litigation proceeding enforcement validity exist patent future patent result invalidation patent substantially reduce protection time time certain individual entity challenge patent pende patent application patent application file collaborative partner result issuance patent result patent provide adequate protection result able prevent party develop compound product closely relate developed develop addition certain country south america africa asia include brazil china provide effective enforcement patent thirdparty manufacturer able sell generic version product country litigation relate sofosbuvir january acquire pharmasset inc pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hepatitis c virus hcv december receive food drug administration fda approval sofosbuvir know commercially sovaldi october receive approval fixeddose combination ledipasvir sofosbuvir ldvsof know commercially harvoni receive number contractual intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit predict ultimate outcome claim patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni party obtain right patent allegedly prevent attempt prevent commercialize sovaldi harvoni example aware patent patent application own party future allege party cover use sovaldi harvoni predict ultimate outcome intellectual property claim relate sovaldi harvoni spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent sovaldi andor harvoni prevent sell product able obtain license patent license available commercially reasonable term interference proceeding litigation idenix pharmaceuticals inc idenix february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pende patent application interference proceed uspto design determine invent subject matter claim party january uspto patent trial appeal board ptab determine pharmasset idenix invent compound dispute accordingly gilead prevail idenix interference idenix appeal ptab decision district court district delaware december receive request uspto declare interference second idenix interference pende patent application idenixs patent patent patent relate idenix patent application issue idenix interference include claim direct method treat hcv nucleoside compound purpose second idenix interference determine invent claim method treat hcv compound similar involved idenix interference march ptab determine pharmasset idenix invent claim method treat hcv idenix appeal decision district court district delaware court appeal federal circuit cafc file motion dismiss appeal delaware respond appeal file cafc believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent involve idenix interference invalid trial issue hold january february november federal court canada render public decision hold idenix patent invalid gilead patent valid month idenix appeal court decision file similar legal action norway oslo district court seek invalidate idenix norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond gilead patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim challenge gilead patent april idenix appeal march decision norwegian court appeal appeal hear march decision take place february january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent monthlong trial complete october sydney decision pende march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent opposition hearing hold february epo rule favor revoke patent march idenix initiate infringement proceeding united kingdom uk germany france allege commercialization sovaldi infringe uk german french counterpart patent trial hold uk october determine issue infringement validity idenix uk patent december high court justice england wale uk court invalidate challenge claim patent multiple ground uk court grant idenix permission appeal december judgment appeal uk court decision schedule july march german court dsseldorf determine idenix patent highly likely invalid stay infringement proceeding pende outcome opposition hearing hold epo february idenix appeal decision german court staying proceeding idenix request french proceeding stay idenix award patent correspond patent japan china event patent issue expect challenge proceeding similar invoke country december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos june court transfer massachusetts litigation district court district delaware district court set trial date october december resolution issue decision district court appeal party cafc idenix acquire merck august acquisition change view lack merit claim idenix merck great resource idenix choose fund litigation high level idenix litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent nos coown isis pharmaceuticals inc august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir court set trial date march lawsuit party appeal decision district court cafc litigation abbvie inc abbvie abbvie obtain patent nos abbvie patent purport cover use combination ldvsof harvoni treatment hcv gilead aware abbvie pende patent application united states grant pende application country publish pende patent application direct use combination treatment hcv specifically combination ldvsof certain application file abbvie patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent uspto gilead invent method treat hcv combination ldvsof february march abbvie respond lawsuit file lawsuit district court district delaware allege fixeddose combination ldvsof infringe patent lawsuit consolidate single action united states party appeal decision district court cafc abbvie patent block delayed commercialization combination product united states canada europe expect foreign patent block delay commercialization world court set trial date september lawsuit additionally abbvie obtain patent purport cover solid oral dosage form contain ledipasvir accordingly file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid relief expect abbvie patent block commercialization combination product court set trial date july august bring impeachment action seek declaration abbvie canadian patent patent purport cover use combination ldvsof treatment hcv invalid day abbvie bring infringement action assert commercialization harvoni canada infringe patent impeachment action stay counterclaimed invalidity infringement proceed trial date set november abbvie file lawsuit regional court dsseldorf infringement quasipatent know utility model utility model unexamine ip right standard patent utility model de purport cover use combination direct acting antiviral includes hcv polymerase inhibitor hcv nsa inhibitor treatment hcv utility model de purport cover solid dispersion include ledipasvir trial date set court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product european patent claim february party file opposition european patent office request revocation grant european patent cover sofosbuvir expire confident strength sofosbuvir patent predict ultimate outcome opposition unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir europe substantially shorten eliminate entirely sofosbuvir patent revoke european patent grant cover sofosbuvir exclusivity base entirely regulatory exclusivity grant european medicine agency ema sovaldi grant regulatory exclusivity prevent generic sofosbuvir enter european union year follow approval sovaldi january lose exclusivity sovaldi prior expect revenue result operation negatively impact year include succeed year exclusivity lose cause stock price decline litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product early patent expiration significant negative effect revenue result operation hiv product november december august receive notice teva pharmaceutical teva submit abbreviate new drug submission and canadian minister health request permission manufacture market generic version truvada atripla viread notice teva allege patent associate truvada atripla viread invalid unenforceable andor infringe teva manufacture use sale generic version product file lawsuit teva federal court canada seek order prohibition approval application december court issue order prohibit canadian minister health approving tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision rule validity patent accordingly issue appeal minister health prohibit approve tevas product appeal hear canadian federal court appeal trial impeachment action court determine validity patent pende impeachment action trial impeachment action schedule november teva successful invalidating patent teva able launch generic version viread truvada atripla products canada prior expiry patent april july receive notices mylan inc mylan submit anda fda request permission manufacture market generic version truvada complera notice mylan allege patent associate truvada complera invalid unenforceable andor infringe mylan manufacture use sale generic version product file lawsuit mylan district court northern district west virginia infringement patent june receive notice mylan submit petition inter parte review ipr ptab allege patent associate tenofovir disoproxil fumarate invalid oppose mylan petition december ptab issue decision deny mylan petition ipr january mylan request rehear basis believe ptab decision wrong august november ptab deny mylan request rehear october reach agreement mylan settle proceeding term settlement agreement confidential june receive notice apotex inc apotex submit and canadian minister health request permission manufacture market generic version truvada separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotex manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval and hearing case schedule april letairis february receive notice watson laboratories inc watson submit anda fda request permission manufacture market generic version letairis notice watson allege patent associate ambrisentan tablet invalid unenforceable andor infringed watson manufacture use sale generic version letairis april file lawsuit watson district court district new jersey june receive notice sigmapharm laboratory llc sigmapharm submit anda fda request permission manufacture market generic version letairis notice sigmapharm allege patent associate ambrisentan tablet invalid unenforceable andor infringe sigmapharm manufacture use sale generic version letairis june file lawsuit sigmapharm district court district new jersey predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit claim patent narrow invalidated patent protection product substantially shorten patent cover product invalidate fda health canada approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation taf litigation january aids healthcare foundation inc ahf file complaint district court northern district california gilead japan tobacco inc japan tobacco international usa japan tobacco emory university emory ahf claim patent nos invalid usc et seq addition ahf claim gilead independently japan tobacco emory violate federal antitrust law market sale tenofovir alafenamide taf offer taf fixeddose combination product elvitegravir cobicistat emtricitabine ahf seek declaratory judgment invalidity patent monetary damage trade secret rely unpatented trade secret improvement unpatente internal knowhow technological innovation particular great deal liposomal manufacturing expertise key component liposomal technology cover patent instead protect trade secret protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independent discover competitor enter dispute ownership invention business result operation adversely affect manufacture raw material manufacturing strategy contract party manufacture majority active pharmaceutical ingredient api solid dose product rely corporate partner manufacture certain product additionally lease manufacturing facility foster city san dimas oceanside california edmonton alberta canada cork ireland manufacture certain product api clinical commercial use manufacturing product contract party manufacture certain product clinical commercial purpose include harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya emtriva tybost vitekta ranexa ambisome zydelig cayston generally use multiple thirdparty contract manufacturer manufacture api product exclusive manufacturer ambrisentan api letairis supplier qualify api letairis rely thirdparty contract manufacturer manufacture tablet capsule product example use multiple thirdparty contract manufacturer tablet harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya tybost vitekta letairis ranexa zydelig hepsera emtriva encapsulation complete thirdparty contract manufacturer addition rely thirdparty contract manufacturer manufacture aseptic product ambisome cayston manufacture agreement corporate partner roche party responsible manufacturing tamiflu agreement roche joint manufacturing committee compose representative roche gilead opportunity review roche exist manufacturing capacity tamiflu global plan manufacture tamiflu astella llc corporate partner lexiscan united states responsible commercial manufacture supply product united states dependent single supplier api lexiscan future product continue develop additional manufacturing capability establish additional thirdparty supplier manufacture sufficient quantity product candidate undertake clinical trial manufacture sufficient quantity product approve commercial sale manufacturing facility foster city california facility conduct process chemistry research development activity manufacture api clinical trial oversee thirdparty contract manufacturer san dimas california facility package label solid dosage oral form product include harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya emtriva ranexa zydelig label hepsera facilities san dimas manufacture ambisome cayston san dimas facility depend single supplier high quality cholesterol api manufacture ambisome exclusive supplier key drug product intermediate ambisome event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need utilize cork ireland facility primarily solid dose tablet manufacturing certain antiviral product product packaging activity package label drug product harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya tybost vitekta label hepsera emtriva facilities cork ireland perform quality control testing final labeling secondary packaging ambisome cayston final release product european union facility distribute product european union international market dublin ireland site edmonton alberta facility canada carry process research scaleup clinical development candidate manufacture api investigational commercial product conduct chemical development activity improve exist commercial manufacturing process manufacture api letairis hepsera edmonton site oceanside california facility design equip produce biologic compound toxicological phase phase clinical study use facility process development manufacture simtuzumab investigational monoclonal antibody candidate gs bulk drug substance investigational mmp mab inhibitor biologic thirdparty manufacturer thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval writeoff cost manufacturing batch fail pass quality inspection meet regulatory approval extent risk materialize affect performance obligation financial result adversely affect addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product believe technology use manufacture product proprietary product manufacture thirdparty contract manufacturer disclose necessary aspect technology enable manufacture product agreement thirdparty manufacturer intend restrict manufacturer reveal technology certain thirdparty manufacturer comply restriction addition thirdparty manufacturer develop technology relate work perform need manufacture product require enter additional agreement thirdparty manufacturer want use technology allow manufacturer use technology thirdparty manufacturer refuse allow use technology demand term use technology acceptable regulation manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation thirdparty manufacturer corporate partner subject current good manufacturing practice extensive regulation govern manufacturing process stability testing record keep quality standard define fda european medicine agency ema similar regulation effect country manufacture operation subject routine inspection regulatory agency example receive letter fda relate extent method revalidation conduct stability program oversight audit trail reviewdata management quality management system gap complete file response observation fda unable remedy deficiency cite fda extent additional deficiency cite fda future inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate delay production market product interrupt anticipate revenue stock price adversely affect access supply material need access certain supply product manufacture product unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue example significant portion raw material intermediate manufacture antiviral product harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya emtriva tybost vitekta supply chinabased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply hiv hcv product meet market need material adverse effect operating result seasonal operation backlog worldwide product sale reflect significant degree seasonality operate market characterize short lead time absence significant backlog believe backlog information material business government regulation operation activity subject extensive regulation numerous government authority united states countries united states european union country drug subject rigorous regulation federal state statute regulation govern testing manufacture safety efficacy labeling storage record keeping approval advertising promotion product result regulation product development product approval process expensive time consume country regulatory agency fda united states european medicines agency european union approve drug sell respective country country general process drug approval united states summarize country include country european union japan similar regulatory structure preclinical testing test drug candidate human study drug laboratory experiment animal generate datum support drug candidate potential benefit safety submit datum fda investigational new drug ind application seek approval test compound human clinical trial fda accept ind drug candidate study human clinical trial determine drug candidate safe effective clinical trial involve separate phase overlap year expensive phase subject considerable regulation follow phase drug candidate give small number healthy human control subject patient suffer indicate disease test safety dose tolerance pharmacokinetic metabolism distribution excretion phase drug candidate give limited patient population determine effect drug candidate treat disease good dose drug candidate possible effect safety risk drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous phase clinical trial phase drug candidate appear effective safe phase clinical trial phase clinical trial commence confirm result phase clinical trial conduct long term involve significantly large population conduct numerous site different geographic region carefully design provide reliable conclusive datum safety benefit drug candidate uncommon drug candidate appear promise phase clinical trial fail rigorous extensive phase clinical trial fda approval process believe datum clinical trial adequate level safety efficacy submit appropriate filing usually form nda supplemental nda fda seek approval sell drug candidate particular use fda hold public hear independent advisory committee expert advisor ask additional question make recommendation drug candidate committee make recommendation fda binding generally follow fda fda agree compound meet require level safety efficacy particular use allow sell drug candidate united states use unusual fda reject application believe drug candidate safe efficacious believe datum submit reliable conclusive point process development drug candidate stop number reason include safety concern lack treatment benefit certain clinical trial currently conduct conduct future complete successfully specified time period choose fda require delay suspend clinical trial time appear patient expose unacceptable health risk drug candidate appear sufficient treatment benefit fda require phase nonregistrational study explore scientific question characterize safety efficacy commercial use drug fda require provide additional data information improve manufacturing process procedure facility require extensive surveillance monitor safety benefit product candidate determine file contain adequate evidence safety benefit drug addition fda approve drug limit use drug fda withdraw approval believe comply regulatory standard problem uncover occur approval addition obtain fda approval drug obtain fda approval manufacturing facility drug sell include company manufacture drug facility subject periodic inspection fda fda approve foreign establishment manufacture product sell united states facility subject periodic regulatory inspection manufacturing facility locate california include oceanside san dimas facility license state california compliance local regulatory requirement manufacture facility locate canada include edmonton alberta facility facility locate near dublin cork ireland obtain local license permit compliance local regulatory requirement drug treat life threaten disease condition adequately address exist drug development program design address unmet medical need designate fast track candidate fda eligible accelerate priority review drug treatment hiv infection designate use president emergency plan aid relief qualify expedite priority review harvoni sovaldi truvada atripla stribild complera viread genvoya zydelig receive accelerate approval priority review drug receive accelerated approval monitor postmarkete clinical trial order confirm safety benefit drug drug subject extensive regulation outside united states european union centralize approval procedure authorize marketing product country european union include major country europe centralize approval procedure approval country european union obtain approval country european union simplified application process mutual recognition procedure decentralize procedure rely principle mutual recognition receive regulatory approval european registration procedure separate pricing reimbursement approval require country european union requirement approval manufacturing facility product approve sale european regulatory authority price reimbursement successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union japan significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service result significant portion sale majority product subject substantial discount rebate obligations united states state aids drug assistance program adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue prior quarter insufficiency federal state fund state reduce eligibility criterion see increase number patient state adap waitlist similar increase future period result reduction federal state adap support patient enrol adap generally receive free product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy price general continue experience global pricing pressure hcv product result increase discount require product delay reimbursement negatively impact future product sale result operation private public payer choose exclude harvoni sovaldi formulary coverage limit type patient coverage provide negatively impact demand revenue harvoni sovaldi change formulary coverage reimbursement level discount rebate offer hcv product payer impact anticipate revenue expect pricing pressure hcv market continue risk factor substantial portion revenue derive sale product treat hcv hiv unable maintain continue increase sale product result operation adversely affect july receive letter senate committee finance senate committee request information support documentation related sovaldi pricing sovaldi united states letter raise concern approach pricing sovaldi affordability impact federal government spend public health december senate committee release result investigation allege engage revenuedriven pricing strategy set sovaldi price gilead disagree conclusion report january receive letter massachusetts attorney general office consider pricing sovaldi harvoni constitute unfair trade practice violation massachusetts law february massachusetts attorney general office serve civil investigative demand request produce document relate hcv product possible result senate committee investigation action take massachusetts attorney general state government result negative publicity negative action harm reputation reduce demand harvoni sovaldi sofosbuvir contain product andor reduce coverage harvoni sovaldi sofosbuvir contain product include federal health care program medicare medicaid state health care program event occur business stock price materially adversely affect country outside united states success commercialize product product candidate develop depend largely obtain maintain government reimbursement country patient unlikely use prescription drug reimburse government recently country european union increase level discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union cost containment pressure european union especially southern europe lead delay treatment patient delay pricing approval month negatively impact commercialization new product reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis tender profit control expect price prescription pharmaceutical decline life product volume increase example anticipate government japan impose significant pricing discount harvoni sovaldi start take effect half united states healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction march healthcare reform legislation adopt united states require rebate discount product reimburse pay public payer include medicaid entity eligible purchase discount product b drug pricing program public health service act adap united states pharmaceutical manufacturer brand drug product require pay portion industry fee know brand prescription drug bpd fee calculate base select government sale year percentage total industry government sale annual bpd fee bill pharmaceutical industry billion increase billion increase peak billion decrease billion bpd fee tax deductible internal revenue service irs issue final regulation accelerate expense recognition criterion fee obligation year fee pay year market share allocate fee determine bpd fee expense million million million expect portion bpd fee increase total annual industrywide fee increase drug patent expire major drug company addition address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare price certain state propose legislation seek regulate pharmaceutical drug pricing propose legislation pass experience additional pricing pressure product addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule health care fraud abuse law antibribery law subject federal state law pertain health care fraud abuse include antikickback law false claim law antikickback law illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business include purchase prescription particular drug breadth statutory provision increase attention give law enforcement authority possible certain practice challenge antikickback similar law false claim law generally prohibit knowingly present cause present false fraudulent claim payment federal certain state payer include medicare medicaid knowingly make cause false record statement material false fraudulent claim sale marketing medical activity subject scrutiny law addition foreign corrupt practice act similar worldwide antibribery law generally prohibit company intermediary make improper payment purpose obtain retain business policy mandate compliance antibribery law operate part world experience governmental corruption degree certain circumstance strict compliance antibribery law conflict local custom practice require interact doctor hospital state control manner different local custom despite train compliance program internal control policy procedure protect reckless criminal act commit employee agent violation fraud abuse law antibribery law punishable criminal andor civil sanction include fine civil monetary penalty possibility exclusion federal health care program include medicare medicaid violation lead imposition corporate integrity agreement similar government oversight program government allege convict violate law disruption business material adverse effect result operation compulsory license number develop country government official interested group suggest pharmaceutical company drug hcv hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example grow attention availability hcv therapy activist advocate increase availability hcv therapy mean include compulsory license past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread addition concern cost availability tamiflu relate potential avian flu pandemic hn influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense india hetero drug limited india certain develop country compulsory license permit generic manufacturing override product patent harvoni sovaldi hiv product tamiflu require grant compulsory license product reduce earning cash flow harm business addition certain country permit enforcement patent thirdparty manufacturer able sell generic version product country example july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale employee january approximately employee believe good relation employee environment health safety strive incorporate sustainability phase drug development business ethical source natural renewable material utilize green chemistry practice continue look way minimize impact environment factor contribute environmental impact include greenhouse gas emission produce employee commute energy water consume facility use hazardous material chemical viruse radioactive compound rd facility refer sustainability report find website wwwgileadcom responsibility measure take mitigate environmental impact business subject number law regulation require compliance federal state local regulation workplace safety protection environment anticipate additional regulation near future law regulation implement consideration mitigate effect climate change mainly cause greenhouse gas emission business energy intensive anticipate subject cap trade system mitigation measure materially impact capital expenditure operation competitive position base current information subject finalization propose regulation believe primary risk relate climate change increase energy cost information subject information requirement exchange act file periodic report proxy statement information sec report proxy statement information obtain visit public reference room sec f street ne washington dc call sec sec send electronic message sec publicinfosecgov send fax sec addition sec maintain website wwwsecgov contain report proxy information statement information issuer file electronically mail address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors section website sec filings financial information section available follow filing soon reasonably practicable electronically file furnished sec annual report quarterly report form q current report form k amendment report file furnish pursuant section exchange act filing available free charge request transaction iran transaction iran require disclosure annual report item risk factor evaluate business carefully consider follow risk addition information annual report manifestation follow risk materially adversely affect business result operation financial condition note factor investor permit private security litigation reform act possible predict identify factor consider follow risk complete statement potential risk uncertainty face substantial portion revenue derive sale product treat hcv hiv unable maintain continue increase sale product result operation adversely affect year end december sale harvoni sovaldi treatment hcv account approximately total product sale certain prior year sale hcv product indicative future sale number warehouse hcv patient diminish quarter anticipate rate new patient start treatment second half indicative pace new patient start approval entry competitor hcv product december january predict extent hcv revenue adversely affect competition product base price andor market share result launch compete regimen experience continue experience increase pricing pressure provide significant discount rebate public private payer order obtain formulary status expand access patient hcv product addition future sale harvoni sovaldi difficult estimate demand depend extent reimbursement hcv product private government payer light continued fiscal debt crisis experience country european union eu japan government announce implement measure manage healthcare expenditure continue experience global pricing pressure result increase discount require product delay reimbursement negatively impact future product sale result operation private public payer choose exclude harvoni sovaldi formulary coverage list limit type patient coverage provide negatively impact demand revenue harvoni sovaldi change formulary coverage reimbursement level discount rebate offer hcv product payer impact anticipate revenue expect pricing pressure hcv market continue example anticipate government japan impose significant pricing discount harvoni sovaldi start take effect half unable maintain forecast hcv sale similar prior year obtain approval reimbursement additional hcv product candidate currently anticipate timeline result operation stock price negatively affect receive substantial portion revenue sale product treatment hiv infection particularly single tablet regimen product stribild compleraeviplera atripla year end december sale hiv product account approximately total product sale hiv product contain tenofovir alafenamide taf tenofovir disoproxil fumarate andor emtricitabine belong nucleoside class antiviral therapeutic treatment paradigm hiv change cause nucleosidebase therapeutic fall favor unable maintain continue increase hiv product sale result operation likely suffer likely need scale operation include spend research development rd effort able sustain increase growth rate sale hcv hiv product number reason include limited follow hcv hiv product long period time patient combination product additional study conduct new issue respect safety resistance interaction drug arise cause provide additional warning contraindication label narrow approve indication halt sale product reduce revenue product mature private insurer government payer reduce reimburse patient product increase pressure reduce price physician benefit hcv hiv product sale hcv hiv product limit new hcv new generic hiv product introduce major market ability maintain pricing market share affect fail commercialize new product expand indication exist product prospect future revenue adversely affect introduce new product increase sale exist product able increase maintain total revenue continue expand rd effort drug development inherently risky product candidate fail drug development process example january announce terminate phase study simtuzumab treatment idiopathic pulmonary fibrosis datum show lack treatment benefit second quarter file nda maa approval dose fixeddose combination emtricitabine taf treatment hiv infection adult pediatric patient age year old combination hiv antiretroviral agent united states european union quarter file nda maa approval single tablet regimen rilpivirine emtricitabine taf united states european union fourth quarter file nda maa approval single tablet regimen sofosbuvir velpatasvir treatment hcv united states european union quarter file nda maa approval taf treatment chronic hepatitis b virus hbv infection united states european union marketing application approve regulatory authority timely basis marketing approval grant product significant limitation use unable file marketing application new product inability accurately predict demand product uptake new product time fluctuation inventory maintain customer make difficult accurately forecast sale cause revenue earning fluctuate adversely affect financial result stock price unable accurately predict demand product include uptake new product demand dependent number factor example hcv product harvoni sovaldi represent significant change treatment paradigm hcvinfecte patient shorten duration treatment reduction elimination need pegylate interferon injection ribavirin certain patient population product represent cure new therapeutic area revenue product difficult investor estimate demand harvoni sovaldi depend availability hcv patient extent reimbursement hcv product private public payer united states country private public payer choose exclude harvoni sovaldi formulary coverage list limit type patient coverage provide negatively impact demand revenue harvoni sovaldi hcv product represent significant change treatment paradigm light launch competitive product sale level prescription growth rate indicative future sale experience continue experience increase pricing pressure united states european union country certain case provide significant discount private public payer order obtain formulary status expand access patient hcv product change formulary coverage reimbursement level discount rebate offer hcv product payer negatively impact anticipate revenue expect pricing pressure continue hcvrelate revenue difficult predict investor widely vary expectation materially higher low actual revenue extent hcv product revenue exceed fall short expectation stock price experience significant volatility year end december approximately product sale united states wholesaler amerisourcebergen corp mckesson corp cardinal health inc wholesaler enter inventory management agreement estimate determine end user demand completely effective match inventory level actual end user demand result change inventory level hold wholesaler cause operating result fluctuate unexpectedly sale wholesaler match end user demand addition inventory hold retail pharmacy nonwholesaler location inventory management agreement control buy pattern adverse change economic condition factor cause retail pharmacy reduce inventory product reduce order wholesaler consequently wholesaler order end user demand change example second half strong wholesaler subwholesaler purchase hiv product result inventory drawdown wholesaler subwholesaler quarter inventory distribution channel fluctuate quarter quarter continue fluctuation earning mismatch prescription demand product revenue addition nonretail sector united states include government institution include state aids drug assistance program adap veterans administration va correctional facility large health maintenance organization tend consistent term buy pattern cause quarter quarter fluctuation necessarily mirror patient demand product federal state budget pressure include sequestration annual grant cycle federal state fund cause purchasing pattern reflect patient demand product example quarter certain prior year observe large nonretail purchase hiv product number state adap exceed patient demand believe purchase drive grant cycle federal adap fund additionally second half experience fluctuation va new patient start purchase pattern va funding expect continue experience fluctuation purchase pattern nonretail customer result fluctuation product sale revenue earning future light global economic downturn budget crisis face european country observe variation purchase pattern induce cost containment measure europe believe measure cause government agency purchaser reduce inventory product distribution channel decrease revenue cause fluctuation product sale earning continue trend future result operation adversely affect current potential future healthcare reform legislative regulatory change government prescription drug procurement reimbursement program occur relatively frequently united states foreign jurisdiction unite states pharmaceutical manufacturer brand drug product require pay portion industry fee know brand prescription drug bpd fee calculate base select government sale year percentage total industry government sale annual bpd fee impose pharmaceutical industry billion increase billion increase peak billion decrease billion internal revenue service irs issue final regulation accelerate expense recognition criterion fee obligation year fee pay year market share allocate fee determine bpd fee expense million million million expect portion bpd fee increase total annual industrywide fee increase drug patent expire major drug company bpd fee tax deductible addition address healthcare reform legislation discussion continue federal level legislation allow require federal government directly negotiate price concession pharmaceutical manufacturer set minimum requirement medicare price certain state propose legislation seek regulate pharmaceutical drug pricing propose legislation pass experience additional pricing pressure product addition state medicaid program request additional supplemental rebate product result increase federal base medicaid rebate private insurer use enactment increase rebate exert pricing pressure product extent private insurer manage care program follow medicaid coverage payment development adverse effect magnify private insurer adopt low payment schedule exist product subject reimbursement government agency party pharmaceutical pricing reimbursement pressure reduce profitability successful commercialization product depend availability governmental thirdparty payer reimbursement cost product relate treatment market sell product government health authority private health insurer organization generally provide reimbursement united states european union japan significant potentially significant market product product candidate government authority thirdparty payer increasingly attempt limit regulate price medical product service significant portion sale majority product subject significant discount list price rebate obligation risk factor substantial portion revenue derive sale product treat hcv hiv unable maintain continue increase sale product result operation adversely affect united states state aids drug assistance program adap purchase significant portion hiv product rely federal supplemental federal state funding help fund purchase product federal state fund available amount sufficient support number patient rely adap sale hiv product negatively impact reduce revenue prior quarter insufficiency federal state fund state reduce eligibility criterion see increase number patient state adap waitlist similar increase future period result reduction federal state adap support patient enrol adap generally receive free product industrysupporte patient assistance program unable access treatment increase emphasis manage healthcare united states country regional pricing reimbursement control european union additional pressure product pricing reimbursement usage adversely affect product sale profitability pressure arise rule practice manage care group judicial decision governmental law regulation relate medicare medicaid healthcare reform pharmaceutical reimbursement policy price general continue experience global pricing pressure hcv product result increase discount require product delay reimbursement negatively impact future product sale result operation private public payer choose exclude harvoni sovaldi formulary coverage limit type patient coverage provide negatively impact demand revenue harvoni sovaldi change formulary coverage reimbursement level discount rebate offer hcv product payer impact anticipate revenue expect pricing pressure hcv market continue risk factor substantial portion revenue derive sale product treat hcv hiv unable maintain continue increase sale product result operation adversely affect july receive letter senate committee finance senate committee request information support documentation related sovaldi pricing sovaldi united states letter raise concern approach pricing sovaldi affordability impact federal government spend public health december senate committee release result investigation allege engage revenuedriven pricing strategy set sovaldi price gilead disagree conclusion report january receive letter massachusetts attorney general office consider pricing sovaldi harvoni constitute unfair trade practice violation massachusetts law february massachusetts attorney general office serve civil investigative demand request produce document relate hcv product possible result senate committee investigation action take massachusetts attorney general state government result negative publicity negative action harm reputation reduce demand harvoni sovaldi sofosbuvir contain product andor reduce coverage harvoni sovaldi sofosbuvir contain product include federal health care program medicare medicaid state health care program event occur business stock price materially adversely affect country outside united states success commercialize product product candidate develop depend largely obtain maintain government reimbursement country patient unlikely use prescription drug reimburse government recently country european union increase level discount require product effort continue country attempt manage healthcare expenditure especially light severe fiscal debt crisis experience country european union cost containment pressure european union especially southern europe lead delay treatment patient delay pricing approval month negatively impact commercialization new product reimbursement policy adversely affect ability sell product profitable basis international market government control price prescription pharmaceutical include implementation reference pricing price cut rebate revenuerelate taxis tender profit control expect price prescription pharmaceutical decline life product volume increase example anticipate government japan impose significant pricing discount harvoni sovaldi start take effect half approximately product sale occur outside united states currency fluctuation hedging expense cause earning fluctuate adversely affect stock price significant percentage product sale denominate foreign currency primarily euro yen face exposure adverse movement foreign currency exchange rate dollar strengthen foreign currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative value sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar use foreign currency exchange forward option contract hedge percentage forecast international sale primarily denominate euro yen hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay foreign currency exchange net hedge unfavorable impact million revenue compare favorable impact million revenue compare predict future fluctuation foreign currency exchange rate dollar dollar appreciate significantly certain currency hedge program sufficiently offset effect appreciation result operation adversely affect stock price decline additionally expense recognize relation hedging activity cause earning fluctuate level hedging expense recognize particular period impact change interest rate spread foreign currency hedge dollar face significant competition face significant competition large global pharmaceutical biotechnology company specialize pharmaceutical firm generic drug manufacturer hcv product harvoni sovaldi compete viekira pak ombitasvir paritaprevir ritonavir tablet copackage dasabuvir tablet market abbvie inc abbvie zepatier elbasvir grazoprevir market merck co inc merck daklinza daclastavir market bristolmyer squibb company bms olysio simeprevir market janssen therapeutic hiv product compete primarily product viiv healthcare viiv market fixeddose combination product compete genvoya stribild compleraeviplera atripla truvada example product market viiv tivicay dolutegravir integrase inhibitor triumeq single tablet triplecombination antiretroviral regimen adversely impact sale hiv product addition lamivudine market joint venture compete emtricitabine active pharmaceutical ingredient emtriva component genvoya stribild compleraeviplera atripla truvada tybost compete ritonavir market abbvie face competition generic hiv product generic version lamivudine combivir lamivudine zidovudine available united states certain country generic version sustiva efavirenz component atripla available canada europe anticipate competition generic efavirenz united states december observe pricing pressure relate sustiva component atripla sale hbv product viread hepsera face competition baraclude entecavir market bms generic entecavir hbv product compete tyzekasebivo telbivudine market novartis pharmaceutical corporation novartis zydelig competes imbruvica ibrutinib market pharmacyclics inc gazyva obinutuzumab market genentech member roche group treanda bendamustine hydrochloride market cephalon inc letairis competes tracleer bosentan opsumit macitentan market actelion pharmaceutical inc adcirca tadalafil market united therapeutics corporation pfizer inc pfizer ranexa compete predominantly generic compound distinct class drug treatment chronic angina united states include generic andor brand betablocker calcium channel blocker longacte nitrate cayston compete tobi tobramycin inhalation solution market novartis tamiflu compete relenza zanamivir market glaxosmithkline product sell generic competitor ambisome compete vfend voriconazole market pfizer caspofungin product develop merck market cancidas united states caspofungin addition aware lipid formulation claim similarity ambisome available outside united states formulation reduce market demand ambisome furthermore manufacture lipid formulation amphotericin b complex formulation find unsafe sale ambisome negatively impact association addition number company pursue development technology competitive exist product research program compete company include specialized pharmaceutical firm large pharmaceutical company act independently pharmaceutical company furthermore academic institution government agency public private organization conduct research seek patent protection establish collaborative arrangement competitive product program competitor gain market share product adversely affect result operation stock price significant safety issue arise market product product candidate future sale reduce adversely affect result operation datum support marketing approval product form basis safety warning product label obtain control clinical trial limit duration case postapproval use product long period time patient underlie health problem take numerous medicine expect continue find new issue safety resistance drug interaction issue require provide additional warning contraindication label narrow approve indication reduce market acceptance product regulatory authority move active transparent pharmacovigilance make great amount standalone safety information clinical trial datum directly available public website mean eg periodic safety update report summarie risk management plan summarie adverse event datum safety information appropriate context expertise misinterpret lead misperception legal action potentially cause product sale stock price decline safety resistance drug interaction issue arise market product sale product limit halt regulatory authority result operation adversely affect operation depend compliance complex fda comparable international regulation failure obtain broad approval timely basis maintain compliance delay halt commercialization product product develop approve marketing sale regulatory authority approve subject extensive regulation food drug administration fda european medicines agency ema comparable regulatory agency country continue clinical trial harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya emtriva tybost vitekta letairis ranexa cayston zydelig hepsera currently approve additional use anticipate file marketing approval additional country additional indication product year product fail receive marketing approval timely basis manufacture sell product subject extensive regulation review discovery previously unknown problem market product problem manufacture safety report promotional activity result restriction product include withdrawal product market fail comply applicable regulatory requirement include related promotion manufacturing subject penalty include fine suspension regulatory approval product recall seizure product criminal prosecution example fda rule require conduct postapproval clinical study assess know risk signal risk identify unexpected risk implement risk evaluation mitigation strategy product include medication guide patient package insert communication plan healthcare provider element fda deem necessary assure safe use drug include impose certain restriction distribution use product failure comply requirement impose sponsor fda result significant civil monetary penalty operating result adversely affect result anticipate timeline clinical trial uncertain support continue development product candidate adversely affect prospect future revenue growth require demonstrate safety efficacy product develop intend use extensive preclinical study clinical trial result preclinical early clinical study accurately predict result later largescale clinical trial successfully complete largescale clinical trial result marketable product example january announce terminate phase trial simtuzumab treatment idiopathic pulmonary fibrosis result show lack treatment benefit product candidate fails achieve primary endpoint clinical trial safety issue arise result clinical trial inadequate support regulatory approval product candidate commercialization product candidate delay halt addition face challenge clinical trial protocol design clinical trial product candidate pipeline delay terminate prospect future revenue growth adversely impact example face numerous risk uncertaintie product candidate include single tablet regimen gs emtricitabine taf treatment hiv single tablet regiman sof velpatasvir gs treatment chronic hcv idelalisib treatment relapse refractory indolent nonhodgkin lymphoma frontline relapse refractory chronic lymphocytic leukemia momelotinib treatment myelofibrosis pancreatic cancer eleclazine g treatment long qt syndrome gs treatment ulcerative colitis currently phase clinical trial prevent completion development product candidate risk include ability enroll patient clinical trial possibility unfavorable result clinical trial need modify delay clinical trial perform additional trial risk fail obtain fda regulatory body approval result product candidate successfully commercialize strategic decision discontinue development product candidate example believe commercialization difficult relative opportunity pipeline program pipeline complete timely basis prospect future revenue growth adversely impact addition clinical trial involve commercial product raise new safety issue exist product turn decrease revenue harm business reliance thirdparty contract research organization conduct clinical trial unable directly control timing conduct expense quality clinical trial extensively outsource clinical trial activity usually perform small portion startup activity inhouse rely independent party contract research organization cro perform clinical study include document preparation site identification screen preparation prestudy visit training program management bioanalytical analysis important aspect service perform cros direct control dispute disruption relationship cro clinical trial delay regulatory submission rely quality validity clinical work perform thirdparty cro cro process methodology result determine invalid inadequate clinical data result relate regulatory approval adversely affect depend relationship company sale marketing performance development commercialization product candidate revenue failure maintain relationship poor performance company dispute company negatively impact business rely number significant collaborative relationship major pharmaceutical company sale marketing performance certain territory include collaboration janssen compleraeviplera bms atripla united states europe canada f hoffmannla roche ltd hoffmannla roche inc roche tamiflu worldwide gsk ambrisentan territory outside united states country rely international distributor sale truvada viread hepsera emtriva ambisome relationship involve clinical development product partner reliance collaborative relationship pose number risk include risk unable control resource corporate partner devote program product dispute arise respect ownership right technology develop corporate partner disagreement corporate partner cause delay termination research development commercialization product candidate result litigation arbitration contract corporate partner fail provide significant protection fail effectively enforce partner fails perform corporate partner considerable discretion elect pursue development additional product pursue alternative technology product collaboration competitor corporate partner marketing right choose pursue compete technology devote few resource marketing product product development distributor corporate partner unable pay particularly light current economic condition give risk great deal uncertainty success current future collaborative effort effort fail product development commercialization new product delay revenue product decline addition letairis cayston distribute thirdparty specialty pharmacy pharmacie specialize dispense medication complex chronic condition require high level patient education ongoing counseling use specialty pharmacy require significant coordination sale marketing medical affair regulatory affair legal finance organization involve risk include limited risk specialty pharmacy provide accurate timely information inventory patient data safety complaint effectively sell support letairis cayston devote resource necessary sell letairis cayston volume time frame expect able satisfy financial obligation cease operation rely party administer letairis education access program leap restrict distribution program design support letairis party provide information education prescriber patient risk letairis confirm insurance coverage investigate alternative source reimbursement assistance ensure fulfillment risk management requirement mandate letairis fda coordinates control dispense patient thirdparty specialty pharmacy failure party specialty pharmacy distribute letairis perform expect result regulatory action fda decrease letairis sale harm business cayston take patient specific inhalation device deliver drug lung patient ongoing distribution cayston entirely reliant manufacturer device manufacturer encounter issue regulatory agency relate device unable supply sufficient quantity device addition manufacturer able provide adequate warranty support device distribute patient respect distribution drug device patient reliant capability specialty pharmacy example distribution channel drug device complicated require coordination reimbursement approval process associate drug device similarly complex device manufacturer unable obtain reimbursement approval receive approval lowerthanexpecte price sale cayston adversely affect previously describe issue limit sale cayston adversely affect financial result success depend significant degree ability defend patent intellectual property right domestically internationally able obtain effective patent protect technology use competitor patent company require stop pay use require technology patent proprietary right important business success depend significant degree ability obtain patent license patent right preserve trade secret defend infringement effort invalidate patent operate infringe intellectual property properly draft enforceable patent difficult competitor use technology create competitive product difficult competitor obtain patent prevent technology create business strategy actively seek patent protection united states internationally file additional patent application appropriate cover improvement compound product technology number foreign patent patent application right patent relate compound product technology certain issue patent enforceable provide adequate protection pende patent application result issue patent patent application confidential period time patent issue result know competitor file patent application technology cover pende application invent file application direct technology subject patent application competitor file patent application receive patent obtain additional patent proprietary right block compete product addition competitor file patent application cover technology participate litigation interference proceeding determine right patent litigation interference proceeding unpredictable expensive ultimately successful result operation adversely affect event patent cover ranolazine compound active ingredient ranexa instead discover sustainedrelease formulation ranolazine achieve therapeutic plasma level patent obtain formulation characteristic plasma level achieve patent cover active ingredient ambisome obtain patent certain product year marketing approval obtain product patent limited life begin run prior commercial sale relate product commercial value patent limit able apply patent term extension supplementary protection certificate country generic manufacturer seek continue seek fda approval market generic version product abbreviate new drug application anda application form typically manufacturer seek approval generic drug description anda litigation note commitment contingency legal proceeding note consolidated financial statement include item annual report risk factor entitle litigation generic manufacturer increase expense continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry begin success depend large ability operate infringe patent proprietary right party infringe valid patent party prevent commercialize product require obtain license party able obtain alternative technology require license reasonable term fail obtain license alternative technology unable develop commercialize product example aware patent relate operation leap restrict distribution program design support letairis aware patent patent application own party claim cover use sofosbuvir description litigation sofosbuvir note commitment contingency legal proceeding note consolidated financial statement include item annual report risk factor entitle party successful establish exclusive right harvoni andor sovaldi expect revenue earning sale harvoni andor sovaldi adversely affect beginning furthermore rely unpatented trade secret improvement unpatente internal knowhow technological innovation protect right mainly confidentiality agreement corporate partner employee consultant vendor agreement provide confidential information develop known individual course relationship keep confidential disclose party specify circumstance case employee agreement provide invention individual employ exclusive property certain party comply confidentiality agreement adequate remedy breach trade secret know independently discover competitor rd agreement invention jointly own corporate partner case exclusive property party certain circumstance difficult determine own particular invention dispute arise invention trade secret confidential information know independently discover competitor enter dispute ownership invention business result operation adversely affect party successful establish exclusive right harvoni andor sovaldi expect revenue earning sale harvoni andor sovaldi adversely affect patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni party obtain right patent allegedly prevent attempt prevent commercialize harvoni sovaldi example aware patent patent application own party allege party cover use harvoni sovaldi predict ultimate outcome intellectual property claim relate harvoni sovaldi spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent harvoni andor sovaldi prevent sell sofosbuvir able obtain license patent license available commercially reasonable term interference proceeding litigation idenix pharmaceuticals inc idenix february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pende patent application interference proceed uspto design determine invent subject matter claim party january uspto patent trial appeal board ptab determine pharmasset idenix invent compound dispute accordingly gilead prevail idenix interference idenix appeal ptab decision district court district delaware december receive request uspto declare interference second idenix interference pende patent application idenixs patent patent patent relate idenix patent application issue idenix interference include claim direct method treat hcv nucleoside compound purpose second idenix interference determine invent claim method treat hcv compound similar involved idenix interference march ptab determine pharmasset idenix invent claim method treat hcv idenix appeal decision district court district delaware court appeal federal circuit cafc file motion dismiss appeal delaware respond appeal file cafc believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent involve idenix interference invalid trial issue hold january february november federal court canada render public decision hold idenix patent invalid gilead patent valid month idenix appeal court decision file similar legal action norway oslo district court seek invalidate idenix norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond gilead patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim challenge gilead patent april idenix appeal march decision norwegian court appeal appeal hear march decision take place february january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent monthlong trial complete october sydney decision pende march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent opposition hearing hold february epo rule favor revoke patent march idenix initiate infringement proceeding united kingdom uk germany france allege commercialization sovaldi infringe uk german french counterpart patent trial hold uk october determine issue infringement validity idenix uk patent december high court justice england wale uk court invalidate challenge claim patent multiple ground uk court grant idenix permission appeal december judgment appeal uk court decision schedule july march german court dsseldorf determine idenix patent highly likely invalid stay infringement proceeding pende outcome opposition hearing hold epo february idenix appeal decision german court staying proceeding idenix request french proceeding stay idenix award patent correspond patent japan china event patent issue expect challenge proceeding similar invoke country december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos june court transfer massachusetts litigation district court district delaware district court set trial date october december resolution issue decision district court appeal party cafc idenix acquire merck august acquisition change view lack merit claim idenix merck great resource idenix choose fund litigation high level idenix litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent nos coown isis pharmaceuticals inc august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir court set trial date march lawsuit party appeal decision district court cafc litigation abbvie abbvie obtain patent nos abbvie patent purport cover use combination ldvsof harvoni treatment hcv gilead aware abbvie pende patent application united states grant pende application country publish pende patent application direct use combination treatment hcv specifically combination ldvsof certain application file abbvie patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent uspto gilead invent method treat hcv combination ldvsof february march abbvie respond lawsuit file lawsuit district court district delaware allege fixeddose combination ldvsof infringe patent lawsuit consolidate single action united states party appeal decision district court cafc abbvie patent block delayed commercialization combination product united states canada europe expect foreign patent block delay commercialization world court set trial date september lawsuit additionally abbvie obtain patent purport cover solid oral dosage form contain ledipasvir accordingly file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid relief expect abbvie patent block commercialization combination product court set trial date july august bring impeachment action seek declaration abbvie canadian patent patent purport cover use combination ldvsof treatment hcv invalid day abbvie bring infringement action assert commercialization harvoni canada infringe patent impeachment action stay counterclaimed invalidity infringement proceed trial date set november abbvie file lawsuit regional court dsseldorf infringement quasipatent know utility model utility model unexamine ip right standard patent utility model de purport cover use combination direct acting antiviral includes hcv polymerase inhibitor hcv nsa inhibitor treatment hcv utility model de purport cover solid dispersion include ledipasvir trial date set court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product european patent claim february party file opposition european patent office request revocation grant european patent cover sofosbuvir expire confident strength sofosbuvir patent predict ultimate outcome action unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir europe substantially shorten eliminate entirely sofosbuvir patent revoke european patent grant cover sofosbuvir exclusivity base entirely regulatory exclusivity grant ema sovaldi grant regulatory exclusivity prevent generic sofosbuvir enter eu year follow approval sovaldi january lose exclusivity sovaldi prior expect revenue result operation negatively impact year include succeed year exclusivity lose cause stock price decline manufacturing problem include thirdparty manufacturer corporate partner cause inventory shortage delay product shipment regulatory approval adversely affect result operation order generate revenue product able produce sufficient quantity product satisfy demand product result complex manufacturing process manufacturing process pharmaceutical product highly regulate regulator shut manufacturing facility believe comply regulation product manufacture facility thirdparty manufacturer corporate partner depend party perform manufacturing activity effectively timely basis majority solid dose product addition roche party responsible manufacturing tamiflu thirdparty manufacturer corporate partner subject good manufacturing practice gmp extensive regulation govern manufacturing process stability testing record keep quality standard define fda ema similar regulation effect country thirdparty manufacturer corporate partner independent entity subject unique operational financial risk control thirdparty manufacturer corporate partner fail perform require impair ability deliver product timely basis receive royalty cause delay clinical trial application regulatory approval writeoff cost manufacturing batch fail pass quality inspection meet regulatory approval addition thirdparty manufacturer corporate partner able produce product limit number facility limited manufacturing capacity certain product extent risk materialize affect performance obligation financial result adversely affect manufacturing operation subject routine inspection regulatory agency example receive letter fda relate extent method revalidation conduct stability program oversight audit trail reviewdata management quality management system gap complete file response observation fda unable remedy deficiency cite fda extent additional deficiency cite fda future inspection currently market product time regulatory approval product development adversely affect risk regulatory agency country marketing application pende undertake similar additional review apply heighten standard review delay regulatory approval product country approval product candidate delay production market product interrupt anticipate revenue stock price adversely affect able obtain material supply necessary conduct clinical trial manufacture sell product limit ability generate revenue need access certain supply product conduct clinical trial manufacture product unable purchase sufficient quantity material find suitable alternate material timely manner development effort product candidate delay ability manufacture product limit limit ability generate revenue supplier key component material name nda maa file fda ema regulatory authority product candidate seek marketing approval significant delay occur qualification new supplier require manufacturer qualified regulatory authority manufacturer continue expend time money effort area production quality control ensure compliance gmp manufacturer subject regular periodic inspection regulatory authority follow initial approval result inspection regulatory authority determine equipment facility laboratory process comply applicable regulation condition product approval regulatory authority suspend manufacturing operation manufacture operation single supplier product suspend unable generate sufficient quantity commercial clinical supply product meet market demand turn decrease revenue harm business addition delivery material supplier interrupt reason unable ship certain product commercial supply supply product development clinical trial addition product material utilize operation facility example manufacture certain drug product intermediate utilize ambisome exclusively facility san dimas california event disaster include earthquake equipment failure difficulty unable replace manufacturing capacity timely manner unable manufacture ambisome meet market need addition depend single supplier amphotericin b active pharmaceutical ingredient ambisome highquality cholesterol manufacture ambisome rely single source active pharmaceutical ingredient find letairis cayston astella llc markets lexiscan united states responsible commercial manufacture supply product united states dependent single supplier active pharmaceutical ingredient lexiscan problem single supplier depend negatively impact development commercialization effort significant portion raw material intermediate manufacture antiviral product include harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya emtriva supply chinabased company result international trade dispute china united states action chinese government limit prevent chinese company supply material adversely affect ability manufacture supply antiviral product meet market need material adverse effect operating result litigation generic manufacturer increase expense continue reduce earning unsuccessful lawsuit claim patent narrow invalidated generic version product launch prior patent expiry approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug anda application form typically manufacturer seek approval generic drug current legal proceeding significance generic manufacturer include mylan april july receive notices mylan inc mylan submit anda fda request permission manufacture market generic version truvada complera notice mylan allege patent associate truvada complera invalid unenforceable andor infringe mylan manufacture use sale generic version product file lawsuit mylan district court northern district west virginia infringement patent june receive notice mylan submit petition inter parte review ipr ptab allege patent associate tenofovir disoproxil fumarate invalid oppose mylan petition december ptab issue decision deny mylan petition ipr january mylan request rehear basis believe ptab decision wrong august november ptab deny mylan request rehear october reach agreement mylan settle proceeding term settlement agreement confidential apotex june receive notice apotex inc apotex submit abbreviate new drug submission ands health canada request permission manufacture market generic version truvada separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotex manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval and hearing case schedule april teva november december august receive notice teva pharmaceutical teva submit abbreviate new drug submission and canadian minister health request permission manufacture market generic version truvada atripla viread notice teva allege patent associate truvada atripla viread invalid unenforceable andor infringe teva manufacture use sale generic version product file lawsuit teva federal court canada seek order prohibition approval application december court issue order prohibit canadian minister health approving tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision rule validity patent accordingly issue appeal minister health prohibit approve tevas product appeal hear canadian federal court appeal trial impeachment action court determine validity patent pende impeachment action trial impeachment action schedule november teva successful invalidating patent teva able launch generic version viread truvada atripla products canada prior expiry patents watson february receive notice watson laboratories inc watson submit anda fda request permission manufacture market generic version letairis notice watson allege patent associate ambrisentan tablet invalid unenforceable andor infringed watson manufacture use sale generic version letairis april file lawsuit watson district court district new jersey sigmapharm june receive notice sigmapharm laboratory llc sigmapharm submit anda fda request permission manufacture market generic version letairis notice sigmapharm allege patent associate ambrisentan tablet invalid unenforceable andor infringe sigmapharm manufacture use sale generic version letairis june file lawsuit sigmapharm district court district new jersey predict ultimate outcome forego action litigation generic manufacturer spend significant resource enforce defend patent unsuccessful lawsuit original claim patent narrow invalidated patent protection truvada viread letairis united states atripla truvada viread canada substantially shorten patent cover product invalidate fda health canada approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation face credit risk emerge market southern european customer adversely affect result operation exposure customer credit risk emerge market southern europe southern european product sale governmentowne support customer southern europe specifically spain italy portugal greece historically subject significant payment delay government funding reimbursement practice result continue result day sale outstanding significantly high country average length time account receivable remain outstanding december account receivable southern europe specifically greece italy portugal spain total approximately billion million great day past include million great day past historically receivable balance certain publiclyowne hospital accumulate period time subsequently settle large lump sum payment pattern experience pharmaceutical company sell directly hospital significant change occur reimbursement practice european government government funding unavailable able collect amount customer result operation adversely affect revenue gross margin reduce import country product available low price price product base local market economic competition differ country country sale country relatively high price reduce product import country low price market case pharmaceutical product sell steeply discount price develop world reexporte european country resold high price happen product particularly truvada viread agree available substantially reduce price country participate gilead access program atripla merck distribute substantially reduce price hiv infect patient develop country agreement revenue adversely affect addition establish partnership indiabase generic manufacturer distribute generic version tenofovir disoproxil fumarate taf contingent regulatory approval develop world country include india expand agreement include right stribild tybost vitekta enter agreement certain indiabase generic manufacturer produce distribute generic emtricitabine develop world include single tablet regimen contain emtricitabine fixeddose combination emtricitabine coformulate hiv medicine start september enter licensing agreement indiabase generic manufacturer produce distribute generic sofosbuvir fixeddose combination ldvsof develop country generic version hiv hcv medication license reexporte united states europe market outside develop world country revenue adversely affect commitment sovaldi available develop world discount price enter agreement sovaldi available egypt country high hcv prevalence world discount sovaldi reexporte develop country united states high price market revenue adversely affect addition purchase product country sell price relatively low resale country sell price relatively high adversely impact revenue gross margin cause sale fluctuate quarter quarter example european union require permit product purchase country sell country purchase product country sell price relatively low resale country sell price relatively high affect inventory level hold wholesaler cause relative sale level country fluctuate quarter quarter reflect actual consumer demand give quarter quarterly fluctuation impact earning adversely affect stock price harm business expensive litigation government investigation increase expense continue reduce earning involve number litigation investigation disputerelate matter require expend substantial internal financial resource expect matter continue require high level internal financial resource foreseeable future matter reduce continue reduce earning description litigation relate sofosbuvir litigation generic manufacturer note commitment contingency legal proceeding note consolidated financial statement include item annual report outcome lawsuit lawsuit brought investigation investigation initiate inherently uncertain adverse development outcome result significant expense monetary damage penalty injunctive relief significantly reduce earning cash flow harm business country require grant compulsory license product patent enforce number develop country government official interested group suggest pharmaceutical company drug hcv hiv infection available low cost alternatively government develop country require grant compulsory license allow competitor manufacture sell version product reduce product sale example grow attention availability hcv therapy activist advocate increase availability hcv therapy mean include compulsory license past certain office government brazil express concern affordability hiv product declare consider issue compulsory license permit manufacture patent product hiv infection include viread addition concern cost availability tamiflu relate potential avian flu pandemic hn influenza generate international discussion compulsory licensing tamiflu patent example canadian government consider allow canadian manufacturer manufacture export active ingredient tamiflu eligible develop develop country canada access medicine regime furthermore roche issue voluntary license permit thirdparty manufacturing tamiflu example roche grant sublicense shanghai pharmaceutical group co ltd china sublicense india hetero drug limited india certain develop country compulsory license permit generic manufacturing override product patent harvoni sovaldi hiv product tamiflu require grant compulsory license product reduce earning cash flow harm business addition certain country permit enforcement patent thirdparty manufacturer able sell generic version product country example july brazilian patent authority reject patent application tenofovir disoproxil fumarate active pharmaceutical ingredient viread high level appeal available brazilian patent authority currently patent brazil brazilian government purchase supply tenofovir disoproxil fumarate generic manufacturer sale generic version product significantly reduce sale adversely affect result operation particularly generic version product import territory exist commercial sale face significant liability result product cover insurance successful claim materially reduce earning testing manufacturing marketing use commercial product product candidate development involve substantial risk product liability claim claim directly consumer healthcare provider pharmaceutical company unable maintain sufficient coverage product liability arise addition cost defend lawsuit pay damage product liability claim exceed coverage unable maintain adequate coverage claim exceed coverage financial condition ability clinically test product candidate market product adversely affect addition negative publicity associate claim regardless merit decrease future demand product impair financial condition business disruption natural manmade disaster harm future revenue worldwide operation subject business interruption stem natural manmade disaster selfinsure corporate headquarters fremont location house majority rd activity la verne san dimas oceanside manufacture facility locate california seismically active region carry adequate earthquake insurance significant recovery time require resume operation financial condition operating result materially adversely affect event major earthquake dependent information technology system infrastructure datum dependent information technology system infrastructure datum multitude complexity computer system inherently vulnerable service interruption destruction malicious intrusion random attack likewise datum privacy security breach employee pose risk sensitive datum include intellectual property trade secret personal information employee patient customer business partner expose unauthorized person public cyberattack increase frequency sophistication intensity cyberattack include deployment harmful malware denialofservice social engineering mean affect service reliability threaten datum confidentiality integrity availability business partner face similar risk security breach system adversely affect security posture invest continue invest protection datum information technology infrastructure assurance effort prevent service interruption identify breach system adversely affect business operation andor result loss critical sensitive information result financial legal business reputational harm addition liability insurance sufficient type cover claim relate security breach cyberattack relate breach change effective income tax rate reduce earning subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis factor favorable unfavorable effect income tax rate include limited change forecast demand hcv product portion nontax deductible annual bpd fee accounting stock option sharebase award merger acquisition ability manufacture product cork ireland facility amortization certain acquisition relate intangible receive tax benefit future level rd spending change mix earning tax jurisdiction operate change overall level pretax earning resolution federal state foreign income tax audits impact income tax provision result mention factor significant negative impact consolidate result operation income tax return subject audit federal state foreign tax authority currently examination internal revenue service tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction resolution exposure report period material impact result operation period fail attract retain highly qualified personnel unable successfully develop new product candidate conduct clinical trial commercialize product candidate future success depend large continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical testing governmental regulation commercialization face competition personnel company university public private research institution government entity organization competition qualified personnel biopharmaceutical field intense limited pool qualified potential employee recruit able attract retain quality personnel acceptable term unsuccessful recruitment retention effort business harm assurance pay dividend continue repurchase stock february announce board director authorize increase dividend program intend pay quarterly dividend share begin second quarter subject quarterly declaration board director board director approve repurchase additional billion common stock commence completion exist billion repurchase plan approve january future declaration time dividend andor time stock repurchase subject capital availability determination board director cash dividend andor stock repurchase good interest stockholder compliance respective law agreement applicable declaration payment cash dividend repurchase stock ability pay dividend andor repurchase stock depend factor cash balance potential future capital requirement strategic transaction include acquisition debt service requirement result operation financial condition factor control board director deem relevant reduction elimination dividend payment dividend program andor stock repurchase negative effect stock price item b unresolved staff comment applicable item property corporate headquarters locate foster city california house administrative manufacturing rd activity rd facility oceanside california fremont california seattle washington alberta canada manufacturing facilities san dimas california cork ireland global operation include office europe north america asia south america africa australia india middle east believe exist property include own lease site good condition suitable conduct business believe capital resource sufficient purchase lease construct additional facility require meet expect longterm growth need item legal proceeding description significant pende legal proceeding note commitment contingency legal proceeding note consolidated financial statement include item annual report incorporate reference item safety disclosure applicable ii item market registrant common equity relate stockholder matter issuer purchase equity security common stock trade nasdaq global select market symbol gild follow table set forth high low intraday sale price share common stock nasdaq global select market period indicate price represent quotation dealer adjustment retail markup markdown commission represent price actual transaction high low high low quarter second quarter quarter fourth quarter february share common stock outstanding hold approximately stockholder record include share hold broker bank nominee dividend initiate quarterly cash dividend share begin second quarter declare pay aggregate cash dividend billion common share item note stockholder equity consolidated financial statement include annual report form k additional information performance graph follow graph compare cumulative total stockholder return past year index standard poor stock index label sp index nasdaq biotechnology index label nbi index stockholder return show graph necessarily indicative future performance endorse prediction future stockholder return comparison cumulative total return investment past year section soliciting material deem file sec incorporate reference filing securities act exchange act date hereof irrespective general incorporation language filing show cumulative return investment assume investment common stock nbi index sp index december dividend reinveste issuer purchase equity securities january board director authorize fiveyear billion stock repurchase program program purchase program open market privately negotiate transaction program commence billion stock repurchase program authorize board director complete quarter spend billion repurchase million share common stock average purchase price share item note stockholder equity consolidated financial statement include annual report information stock repurchase program table summarize stock repurchase activity month end december maximum fair value total number average price pay total number share purchase share purchase share purchase share publicly announce program program thousand dollar thousand million october october november november december december total stock repurchase program difference total number share purchase total number share purchase publicly announce program share common stock withhold employee restrict stock award order satisfy applicable tax withholding obligation february enter accelerate share repurchase program asr repurchase billion common stock pay billion receive million share common stock represent approximately total share expect deliver asr total number share receive asr base average price common stock purchase period end april february board director authorize new billion share repurchase program program commence completion program purchase program open market privately negotiate transaction item select financial datum gilead sciences inc select consolidated financial datum million share datum year end december consolidated statement income datum total revenue total cost expense income operation provision income taxis net income attributable gilead net income share attributable gilead common stockholder basic share share calculationbasic net income share attributable gilead common stockholder dilute share share calculationdilute cash dividend declare share december consolidated balance sheet datum cash cash equivalent marketable security work capital total asset longterm obligation senior unsecured note convertible senior note credit facility retain earning total stockholder equity item management discussion analysis description result operation issue billion principal senior unsecured note register offering repay million principal balance convertible senior note million cash relate conversion spread note issue billion principal senior unsecured note register offering repay million principal balance convertible senior note billion cash relate conversion spread note million senior unsecured note million fiveyear revolve credit facility agreement fiveyear revolve credit agreement repay billion principal balance convertible senior note repay million fiveyear revolve credit agreement complete acquisition pharmasset inc recognize consideration transfer billion primarily record intangible asset finance transaction approximately billion cash hand billion bank debt issue january billion senior unsecured note issue december prior year amount reclassify conform current presentation item management discussion analysis financial condition result operation follow management discussion analysis financial condition result operation mda intend help reader understand result operation financial condition mda provide supplement read conjunction audit consolidated financial statement accompany note consolidated financial statement disclosure include annual report include disclosure item risk factor consolidate financial statement prepare accordance generally accept accounting principle present dollar management overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world gilead primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis c virus hcv infection chronic hepatitis b virus hbv infection cardiovascular hematologyoncology inflammationrespiratory operation country worldwide headquarters foster city california continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy portfolio market product include ambisome atripla cayston compleraeviplera emtriva genvoya harvoni hepsera letairis ranexa sovaldi stribild tamiflu truvada tybost viread vitekta zydelig international commercial sale operation marketing subsidiary north south america europe asiapacific sell distribute certain product corporate partner royaltypaye collaborative agreement business highlight continue advance product pipeline therapeutic area goal deliver bestinclass drug advance current standard care andor address unmet medical need highlight activity include antiviral program food drug administration fda european commission approve genvoya treatment hiv infection genvoya tenofovir alafenamide tafbase regiman submit marketing application fda european medicines agency ema investigational oncedaily single tablet regimen combine emtricitabine mg taf mg rilpivirine mg rftaf janssen sciences ireland uc janssen pharmaceutical companies johnson johnson treatment hiv infection adult pediatric patient year age old submit marketing application fda ema dose ftaf mg mg treatment hiv infection adult pediatric patient age year old combination hiv antiretroviral agent fda approve harvoni expand use patient genotype hcv infection patient coinfecte hiv addition harvoni plus ribavirin week approve alternate therapy week harvoni treatmentexperience genotype patient cirrhosis japanese ministry health labour welfare approve sovaldi suppression viremia patient genotype chronic hcv infection compensate cirrhosis harvoni oncedaily singletablet regimen treatment chronic hcv genotype infection adult compensate cirrhosis treatment duration week submit marketing application fda ema investigational oncedaily fixeddose combination nucleotide analog polymerase inhibitor sofosbuvir sof mg velpatasvir vel mg investigational pangenotypic nsa inhibitor treatment genotype chronic hcv infection receive reimbursement approval sovaldi harvoni country european union cardiovascular program fda approve use letairis ambrisentan combination tadalafil treatment pulmonary arterial hypertension pah reduce risk disease progression hospitalization worsen pah improve exercise ability hematologyoncology program file supplemental new drug application use zydelig idelalisib combination ofatumumab previouslytreate patient chronic lymphocytic leukemia inflammationrespiratory program enter collaboration license agreement galapagos nv effective january development commercialization jakselective inhibitor filgotinib inflammatory disease indication collaboration represent opportunity add complementary clinical program grow inflammation research development effort financial highlight total revenue increase billion total product sale increase billion compare billion billion respectively drive primarily sale harvoni increase sale hiv single tablet regimen product stribild compleraeviplera recently launch genvoya partially offset decrease sale sovaldi uptake harvoni harvoni approve united states october european union november japan july product sale billion compare billion europe product sale billion compare billion sale international location billion compare billion primarily sale sovaldi harvoni japan rd expense increase billion compare continue investment progression expansion product pipeline sell general administrative sga expense increase billion compare increase cost support business expansion net income attributable gilead billion diluted share compare billion diluted share primarily launch harvoni partially offset decline sale sovaldi increase operating expense december cash cash equivalent marketable security total billion generate billion operating cash flow issue senior unsecured note total aggregate principal billion note pay billion settle million warrant relate convertible senior note repurchase million share common stock aggregate billion initiate quarterly cash dividend share second quarter pay total billion dividend shareholder outlook continue focus key operating objective include progression product pipeline continue uptake commercial product research development rd perspective continue invest conduct new ongoing clinical study support exist product product candidate expect forward number latestage clinical study new product candidate plan file marketing application product candidate therapeutic area commercial perspective continue focus support uptake genvoya prepare additional anticipate launch new taf base regimen ftaf rftaf continue promote use exist commercial product hcv continue focus advance care people disease regardless genotype disease severity sofvel approve regiman offer high sustain viral response rate week treatment patient hcv genotype plan buildout expand commercial infrastructure globally additionally focus near term long term objective help patient world progress subject number uncertainty include limited continuation uncertain global macroeconomic environment adoption additional pricing measure reduce healthcare spend particularly hcv volatility foreign currency exchange rate inaccuracy hcv patient start estimate additional competitive launch hcv increase discount chargeback rebate ongoing private public payer negotiation large anticipate shift payer mix highly discount payer segment result operation total revenue follow table summarize product sale royalty contract revenue million percentage change change revenue product sale royalty contract revenue total revenue product sale total product sale billion compare billion billion drive primarily increase antiviral product sale antiviral product sale include product hiv liver disease area billion billion billion sequential increase antiviral product sale drive primarily launch sovaldi harvoni increase sale launch harvoni geography partially offset yearoveryear decline sovaldi sale patient prescribe harvoni instead sovaldi hiv product contribute sale increase primarily increase sale new hiv singletablet regimen stribild compleraeviplera recently launch genvoya partially offset decline atripla sale volume product sale include letairis ranexa ambisome zydelig billion increase compare billion increase product sale billion approximately product sale generate outside united states face exposure adverse movement foreign currency exchange rate primarily euro yen foreign currency exchange contract hedge percentage foreign currency exposure foreign currency exchange net hedge unfavorable impact million revenue compare favorable impact million revenue compare record product sale net estimate mandatory supplemental discount government payer addition discount private payer include rebate chargeback cash discount prompt payment distributor fee relate cost deduction generally refer grossto net deduction total billion gross product sale billion billion billion billion gross product sale relate government rebate chargeback billion relate cash discount prompt payment distributor fee relate cost anticipate grosstonet deduction attributable hcv product sale exceed overall gross tonet order obtain formulary status expand access patient result launch compete regimen experience continue experience increase pricing pressure decline grosstonet deduction percentage gross product sale compare primarily change payer mix reflect high proportion product sale private payer compare give launch sovaldi december harvoni october product sale united states increase billion compare billion primarily sale harvoni increase sale stribild truvada complera partially offset decline sale sovaldi product sale united states increase compare billion primarily sale sovaldi harvoni increase sale stribild complera product sale europe increase billion compare billion primarily sale harvoni product sale europe increase billion compare billion primarily sale sovaldi increase sale eviplera stribild foreign currency exchange net hedge unfavorable impact million european product sale compare favorable impact million european product sale compare product sale international location increase billion compare billion primarily launch japan sovaldi march harvoni july product sale international location increase compare million primarily launch sovaldi geography hcv product harvoni sovaldi recently launch historical sale indicative future sale united states number hcv new patient start diminish quarter indicative rapid initiation treatment warehoused patient follow flatten patient remain quarter anticipate rate new patient start treatment second half indicative pace new patient start europe expect early launch market stabilize new market ramp treatment japan patient number difficult predict hcv product recently launch additionally anticipate government japan impose significant pricing discount harvoni sovaldi start take effect half follow table summarize period period change product sale million percentage change change antiviral product harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya antiviral total antiviral product product letairis ranexa ambisome zydelig total product sale percentage meaningful antiviral product follow additional discussion result product harvoni harvoni sale account total antiviral product sale respectively harvoni approve fda october european commission november japanese ministry health labour welfare mhlw july harvoni approve oncedaily single tablet regimen treatment chronic hcv genotype net product sale harvoni united states billion billion drive product launch net product sale harvoni europe billion million launch harvoni number country include france germany uk italy spain net product sale harvoni international location billion million primarily product launch japan sovaldi sovaldi sale account total antiviral product sale respectively sovaldi approve fda december european commission january japan march net product sale sovaldi decrease billion compare billion primarily volume decline united states patient prescribe harvoni instead sovaldi partially offset volume increase japan europe continue launch sovaldi country net product sale sovaldi billion united states billion europe billion international location primarily japan net product sale sovaldi billion united states billion europe million international location truvada truvada sale account total antiviral product sale respectively truvada sale increase billion compare billion compare billion primarily sale volume growth increase average net selling price united states net product sale truvada billion united states billion europe million international location net product sale truvada billion united states billion europe million international location net product sale truvada billion united states billion europe million international location atripla atripla sale account total antiviral product sale respectively atripla sale decrease billion compare billion compare billion primarily decline volume doctor prescribe new treatment compleraeviplera stribild efavirenz component atripla gross margin zero comprise billion billion billion atripla sale respectively net product sale atripla billion united states million europe million international location net product sale atripla billion united states million europe million international location net product sale atripla billion united states billion europe million international location generic version bristolmyers squibb company sustiva efavirenz component atripla available canada europe available united states observe pricing pressure relate efavirenz component atripla sale observe meaningful splitting atripla single tablet regimen stribild stribild sale account total antiviral product sale respectively stribild sale increase billion compare billion compare million primarily increase sale volume united states europe net product sale stribild billion united states million europe net product sale stribild billion united states million europe net product sale stribild primarily attributable sale united states million compleraeviplera compleraeviplera sale account total antiviral product sale respectively compleraeviplera sale increase billion compare billion compare million drive primarily sale volume growth united states europe net product sale compleraeviplera million united states million europe net product sale compleraeviplera million united states million europe net product sale compleraeviplera million united states million europe viread viread sale account total antiviral product sale respectively viread sale increase compare increase compare drive primarily sale volume united states international location net product sale viread million united states million europe million international location net product sale viread million united states million europe million international location net product sale viread million united states million europe million international location product product include letairis ranexa ambisome zydelig billion billion billion yearoveryear increase product sale primarily increase sale volume letairis zydelig royalty contract revenue follow table summarize period period change royalty contract revenue million percentage change change royalty contract revenue royalty contract revenue primarily include royalty revenue f hoffmanla roche ltd sales tamiflu majority royalty recognize quarter follow quarter correspond product sale occur cost good sell product gross margin follow table summarize period period change product sale cost good sell product gross margin million percentage change change total product sale cost good sell product gross margin product gross margin increase compare primarily change product mix atripla sale include efavirenz component gross margin zero decline hcv sale increase percentage product sale product gross margin increase compare primarily change product mix result launch sovaldi harvoni research development expense follow table summarize period period change rd expense million percentage change change research development rd expense summarize consist primarily clinical study perform contract research organization material supply license fee milestone payment collaboration arrangement personnel cost include salary benefit stockbase compensation overhead allocation consist support facilitiesrelate cost track total rd expense product candidate therapeutic area development phase manage rd expense identify rd activity anticipate perform give period prioritize effort base scientific datum probability successful development market potential available human capital resource consideration continually review rd pipeline status development necessary reallocate resource rd portfolio believe good support future growth business follow table provide breakout rd expense major cost type million percentage clinical study outside service personnel infrastructure expense facility cost total rd expense increase million compare primarily increase personnel infrastructure expense million facility cost million support ongoing clinical study activity geographic expansion discuss clinical study outside service include onetime item million collaboration acquisition relate expense purchase fda priority review voucher rd expense increase million compare primarily increase clinical study outside service increase clinical study outside service include onetime item million collaboration acquisition relate expense purchase fda priority review voucher million expense relate progression clinical study activity primarily oncology hiv area personnel infrastructure expense increase million support ongoing clinical study activity geographic expansion market product support expect rd expense increase support expansion clinical study therapeutic area include liver disease hiv inflammation sell general administrative expense follow table summarize period period change sga expense million percentage change change sell general administrative sga expense relate sale marketing finance human resource legal administrative activity expense primarily comprise facility overhead cost information technology infrastructure outside marketing advertising legal expense general administrative cost sga expense include brand prescription drug bpd fee enact affordable care act sga expense increase million compare primarily increase million headcountrelate marketing expense support growth geographic expansion business partially offset decrease bpd fee expense million change estimate portion fee relate prior year sga expense increase billion compare primarily increase headcountrelate expense million support ongoing growth expansion business include commercial expansion relate launch sovaldi harvoni increase bpd fee expense million internal revenue service irs issue final regulation accelerate expense recognition criterion fee obligation year fee pay year market share allocate fee determine result recognize million sga expense previously accrue bpd fee expense million million million bpd fee tax deductible expect sga expense increase compare support continue buildout expansion commercial infrastructure globally support product increase estimate million bpd fee interest expense interest expense increase million compare million increase primarily issuance billion aggregate principal senior unsecured note note issuance billion aggregate principal senior unsecured note note interest expense increase million compare million increase primarily result issuance note offset repayment senior unsecured note issue march december note conversion maturity convertible senior note note partial conversion convertible senior note note collectively note note income expense net income expense net increase million compare million primarily high interest income result portfolio earn high yield high cash balance income expense net insignificant provision income taxis provision income tax billion billion billion respectively effective tax rate differ federal statutory rate primarily certain operating earning nonus subsidiary consider indefinitely reinveste tax credit partially offset state taxis portion nontax deductible bpd fee amortization expense intangible asset relate sofosbuvir receive tax benefit provide income taxis undistribute earning foreign operation intend indefinitely reinveste foreign subsidiary effective tax rate differ federal statutory rate primarily certain operating earning nonus subsidiary consider indefinitely reinveste tax credit partially offset state taxis portion nontax deductible bpd fee amortization expense intangible asset relate sofosbuvir receive tax benefit effective tax rate differ federal statutory rate primarily retroactive extension federal research tax credit january federal research tax credit certain operating earning nonus subsidiary consider indefinitely reinveste partially offset state taxis portion nontax deductible bpd fee amortization expense intangible asset relate sofosbuvir contingent consideration expense relate certain acquisition receive tax benefit subsequent event galapago enter license collaboration agreement galapagos nv galapagos clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor investigate inflammatory disease indication term agreement effective january upfront license fee payment million million equity investment galapago addition galapago eligible receive development regulatory milestonebase payment million salesbase milestone payment million tiere royalty global sale profit split potential copromotion territory liquidity capital resource believe exist capital resource supplement cash flow generate operating activity adequate satisfy capital need foreseeable future follow table summarize cash cash equivalent marketable security work capital million december cash cash equivalent marketable security work capital cash cash equivalent marketable security cash cash equivalent marketable security total billion december increase billion compare billion december generate billion cash flow operation receive billion net proceed note repurchase billion common stock additionally utilize billion settle million warrant relate note warrant pay cash dividend billion cash cash equivalent marketable security total billion december increase billion compare billion december generate billion cash flow operation receive billion issuance note repay billion debt net convertible note hedge repurchase billion common stock pay approximately billion settle warrant expire relate note warrant total cash cash equivalent marketable security december approximately billion generate operation foreign jurisdiction intend use foreign operation rely unrepatriate earning source fund domestic business expect sufficient cash flow borrowing capacity united states fund domestic operational strategic need work capital work capital billion december increase billion work capital december drive primarily increase cash cash equivalent shortterm marketable security increase account receivable partially offset increase accrue government rebate work capital billion december increase billion work capital december drive primarily positive cash flow operation increase cash cash equivalent issuance note partially offset cash pay settle convertible senior note warrant repayment bank debt repurchase common stock cash flow follow table summarize cash flow activity million cash provide operating activity invest activity financing activity cash provide operating activity cash provide operating activity billion consist primarily net income billion adjust noncash item billion depreciation amortization expense million stockbase compensation expense billion net cash inflow relate change operate asset liability cash flow operation decrease future continue cash payment relate accrued government rebate cash provide operating activity billion consist primarily net income billion adjust noncash item billion depreciation amortization expense million stockbase compensation expense partially offset million net cash outflow relate change operate asset liability cash provide operating activity billion consist primarily net income billion adjust noncash item million depreciation amortization expense million stockbase compensation expense partially offset million net cash outflow relate change operate asset liability cash investing activity cash investing activity billion consist primarily billion net purchase marketable security million capital expenditure relate expansion business cash investing activity billion consist primarily billion net purchase marketable security million capital expenditure relate expansion business cash investing activity million consist primarily million acquisition ym biosciences net cash acquire million capital expenditure primarily relate construction progress associate new facility headquarters support ongoing growth business partially offset million net proceed sale marketable security cash financing activity cash financing activity billion consist primarily billion repurchase common stock stock repurchase program billion settle million warrant billion pay dividend payment primarily offset billion net proceed issuance note cash financing activity billion consist primarily billion repay debt net convertible note hedge billion repurchase common stock stock repurchase program billion settle warrant payment primarily offset billion net proceed issuance note cash financing activity billion consist primarily billion repay debt financing include maturity convertible senior note note conversion note billion settle warrant relate note settle august million repurchase common stock stock repurchase program cash outflow partially offset proceed billion relate convertible note hedge debt credit facility longterm obligation summary borrowing financing arrangement include item note debt credit facility consolidate financial statement include annual report debt financing september issue note aggregate principal billion issue note aggregate principal billion note note issue general corporate purpose include repayment debt work capital payment dividend repurchase outstanding common stock pursuant authorize share repurchase program convertible senior note repayment warrant settlement portion note settle repay million principal balance relate note pay million cash relate conversion spread note represent conversion value excess principal receive million cash convertible note hedge relate note enter modify agreement warrant counterpartie change time expiration million warrant agreement allow settle million warrant option cash share accord term agreement warrant expire tradingday period commence end june exercise option settle cash result pay billion market value common stock time exercise warrant exceed strike price note mature portion note convert repay million principal balance relate note pay billion cash relate conversion spread note represent conversion value excess principal receive billion cash convertible note hedge relate note exercise option settle cash warrant result pay billion settle warrant market value common stock time exercise warrant exceed strike price million share common stock underlie warrant strike price share expire tradingday period commence august end september december million outstanding convertible senior note note mature early repurchase convert remain million outstanding warrant strike price share adjust quarterly dividend distribution expire tradingday period commencing august change term remain million warrant credit facility january enter fiveyear billion revolve credit facility credit agreement fiveyear revolve credit agreement borrow million thereunder repay million fiveyear revolve credit agreement repay remain balance million outstanding fiveyear revolve credit agreement contain customary representation warranty affirmative negative financial maintenance covenant event default loan bear interest eurodollar rate plus applicable margin ii base rate plus applicable margin define credit agreement reduce commitment prepay loan time premium penalty require comply certain covenant credit agreement note indenture december violation covenant amount outstanding credit facility capital return program stock repurchase programs january board director authorize fiveyear billion stock repurchase program program program commence billion stock repurchase program authorize board director complete quarter billion repurchase program authorize board director january complete december remain authorize repurchase program billion follow table summarize stock repurchase abovedescribe program million share repurchase retire february enter accelerate share repurchase program asr repurchase billion common stock pay billion receive million share common stock represent approximately total share expect deliver asr total number share receive asr base average price common stock purchase period end april february board director authorize new billion share repurchase program program commence completion program purchase program open market privately negotiate transaction dividend second quarter begin pay quarterly dividend common stock pay cash dividend billion share february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march capital resource believe exist capital resource supplement cash flow generate operation adequate satisfy capital need foreseeable future future capital requirement depend factor include limited follow commercial performance current future product progress scope rd effort include preclinical study clinical trial cost timing outcome regulatory review expansion sale marketing capability administrative expense possibility acquire additional manufacturing capability office facility possibility acquire company new product cost associate settlement conversion convertible senior note relate warrant establishment additional collaborative relationship company cost associate defense settlement adverse result litigation government investigation future require additional funding form proceed equity debt financing fund require guarantee available favorable term critical accounting policy estimate judgment discussion analysis financial condition result operation base consolidated financial statement prepare accordance generally accept accounting principle preparation financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate believe follow critical accounting policy reflect significant judgment estimate preparation consolidated financial statement revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectability reasonably assure record product sale net estimate mandatory supplemental discount government payer addition discount private payer relate charge generally refer grosstonet deduction record period relate sale occur government rebate chargeback represent majority grosstonet deduction require complex significant judgment management estimate assess period update reflect current information government rebate chargeback government rebate chargeback include amount pay payer healthcare providers united states include medicaid rebate adap veterans administration public health service discount rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan qualified program purchase product wholesaler distributor low contractual price wholesaler distributor charge difference acquisition cost low contractual price consolidate allowance government chargeback payable direct customer classify reduction account receivable total million december million december consolidated allowance government rebate pay party direct customer record accrue government rebate consolidated balance sheet total billion december billion december allowance government rebate chargeback estimate base product sell historical utilization rate pertinent party industry information estimate patient population know market event trend channel inventory datum andor market datum consider new information change program regulation guideline impact actual rebate andor expectation future utilization rate program believe methodology use estimate government rebate chargeback reasonable appropriate give current fact circumstance actual result differ significantly estimate year actual government rebate chargeback claim prior period vary estimate follow table summarize consolidated activity government rebate chargeback account million balance begin decreaseincrease accrue government rebate chargeback year product sale payment balance end year year end december activity relate sale activity relate sale prior total year end december activity relate sale activity relate sale prior total majority increase accrue government rebate chargeback compare drive increase sale volume allowance doubtful account maintain allowance doubtful account estimate loss result inability customer require payment allowance base analysis factor include limited contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice financial condition customer economic environment operate deteriorate result inability payment additional allowance require believe allowance doubtful account adequate significant deterioration factor materially change expectation result increase allowance doubtful account december account receivable net billion billion allowance doubtful account million million respectively valuation intangible asset conjunction business combination record intangible asset primarily relate inprocess research development iprd project total intangible asset billion december billion december identifiable intangible asset measure respective fair value acquisition date model value intangible asset require use significant estimate assumption include limited estimate revenue operate profit relate product product candidate probability success unapproved product candidate consider stage development time resource need complete development approval product candidate life potential commercialize product associate risk include inherent difficulty uncertaintie develop product candidate obtain fda regulatory approval risk relate viability potential alternative treatment future target market believe fair value record intangible asset acquire connection business combination base reasonable estimate assumption give fact circumstance relate valuation date intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort development complete generally occur regulatory approval market product obtain associate asset deem finitelived amortize base respective estimate useful life point time period asset consider indefinite live amortize test impairment annual basis annual test aware event change indicate likely fair value iprd project respective carrying amount fair value indefinite live intangible asset dependent assumption expect timing probability achieve specify milestone change project revenue change discount rate significant judgment employ determine assumption change assumption significant impact result operation give period intangible asset finite useful life amortize estimate useful life primarily straightline basis intangible asset finite useful life review impairment fact circumstance suggest carry value asset recoverable tax provision estimate income tax provision include defer tax asset liability base significant management judgment evaluate realization portion defer tax asset quarterly basis record valuation allowance reduce defer tax asset amount likely realize consider future taxable income ongoing tax planning strategy historical financial performance assess need valuation allowance expect realize defer tax asset previously record valuation allowance reduce valuation allowance period determination subject income taxis unite states foreign jurisdiction include ireland economic political condition country actively consider change exist tax law predict form time potential legislative change material adverse impact result operation addition significant judgment require determine worldwide provision income taxis record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period december total federal state foreign unrecognized tax benefit billion million respectively total unrecognized tax benefit billion million december respectively recognize reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return subject audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position balance sheet arrangement balance sheet arrangement define item aii regulation sk contractual obligation contractual obligation consist debt obligation operating lease capital commitment purchase obligation active pharmaceutical ingredient inventoryrelate item clinical trial contract follow table summarize significant enforceable legally bind obligation future commitment obligation relate contract likely continue regardless fact certain obligation cancelable december million payment period contractual obligation total year year year year debt operating lease obligation capital commitment purchase obligation clinical trial total debt obligation include senior unsecured note convertible senior note interest payment incur calculate base term relate note information item note debt credit facility consolidate financial statement include annual report form k december firm capital project commitment approximately million primarily relate construction new building december firm purchase commitment relate active pharmaceutical ingredient certain inventoryrelate item amount include minimum purchase requirement addition commit potential future milestone payment party license collaboration development arrangement payment agreement generally payable achievement certain developmental regulatory andor commercial milestone achievement milestone probable reasonably estimable contingency record consolidated balance sheet include table december clinical study clinical trial phase significant clinical trial expenditure contract research organization cro material contract cro cancelable historically cancel contract amount reflect commitment base exist contract reflect future modification termination exist contract anticipate potential new contract total gross unrecognized tax benefit liability include interest penalty billion december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority unrecognize tax benefit include current longterm income taxis payable longterm defer tax asset consolidate balance sheet include table recent accounting pronouncement information require item include item note organization summary significant accounting policy consolidate financial statement include annual report item quantitative qualitative disclosure market risk expose market risk result change foreign currency exchange rate interest rate credit risk reduce certain risk enter type foreign currency interest rate derivative hedging transaction follow investment guideline monitor outstanding receivables risk management program foreign currency exchange risk operation include manufacture sale activity united states canada ireland sale activity country outside united states include europe asia pacific result financial result significantly affect factor change foreign currency exchange rate weak economic condition foreign market distribute product operating result expose change foreign currency exchange rate dollar foreign currency significant euro yen dollar strengthen currency relative value sale respective foreign currency decrease conversely dollar weaken currency relative amount sale increase overall net receiver foreign currency benefit weak dollar adversely affect strong dollar relative foreign currency transact significant amount business approximately product sale denominate foreign currency partially mitigate impact change currency exchange rate net cash flow foreign currency denominate sale enter foreign currency exchange forward option contract hedge certain monetary asset liability denominate foreign currency reduce eliminate exposure currency fluctuation date transaction record date cash collect pay general market risk contract offset correspond gain loss transaction hedge december open foreign currency forward contract notional amount billion billion respectively hypothetical adverse movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract hypothetical movement foreign currency exchange rate compare dollar relative exchange rate december resulted reduction fair value contract approximately million date realize negatively affect earning remain life contract analysis consider impact hypothetical change foreign currency exchange rate anticipated transaction foreign currency sensitive instrument design offset interest rate risk portfolio availableforsale marketable security fix variable rate liability create exposure interest rate risk respect investment portfolio adhere investment policy require limit amount invest security base credit rating maturity industry group investment type issuer security issue government goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return follow table summarize expect maturity average interest rate interestgenerate asset fix interestbeare liability december millions percentage expect maturity total fair total value asset availableforsale debt security average interest rate liabilitie debt average interest rate december debt consist senior unsecured note convertible senior note aggregate carrying value billion instrument bear interest fix rate change interest rate affect interest expense cash flow fair value instrument fluctuate interest rate change note debt credit facility consolidate financial statement include annual report additional information credit risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe december account receivable southern europe specifically greece italy portugal spain total approximately billion million great day past include million great day past december account receivable southern europe specifically greece italy portugal spain total approximately million million great day past include million great day past date experience significant loss respect collection account receivable item financial statement supplementary datum gilead sciences inc index consolidated financial statement supplementary data year end december content report independent register public accounting firm audit consolidated financial statement consolidate balance sheet consolidate statement income consolidate statement comprehensive income consolidate statement stockholder equity consolidate statement cash flow note consolidated financial statement select quarterly financial information unaudite report independent register public accounting firm board director stockholder gilead sciences inc audit accompany consolidated balance sheet gilead sciences inc december relate consolidated statement income comprehensive income stockholder equity cash flow year period end december audits include financial statement schedule list index item financial statement schedule responsibility company management responsibility express opinion financial statement schedule base audit conduct audits accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance financial statement free material misstatement audit include examine test basis evidence support amount disclosure financial statement audit include assess accounting principle significant estimate management evaluate overall financial statement presentation believe audits provide reasonable basis opinion opinion financial statement refer present fairly material respect consolidate financial position gilead sciences inc december consolidate result operation cash flow year period end december conformity generally accept accounting principle opinion relate financial statement schedule consider relation basic financial statement take present fairly material respect information set forth audit accordance standard public company accounting oversight board united states gilead sciences inc internal control financial reporting december base criterion establish internal controlintegrate framework issue committee sponsor organization treadway commission framework report date february express unqualified opinion thereon ernst young llp redwood city california february gilead sciences inc consolidated balance sheet million share amount december asset current asset cash cash equivalent shortterm marketable security account receivable net allowance december december inventory defer tax asset prepay current asset total current asset property plant equipment net longterm portion prepay royalty longterm defer tax asset longterm marketable security intangible asset net goodwill longterm asset total asset liability stockholder equity current liability account payable accrue government rebate accrue liability defer revenue current portion longterm debt obligation net total current liability longterm debt net longterm income taxis payable longterm obligation commitment contingency note equity component currently redeemable convertible note stockholder equity prefer stock par value share share authorize outstanding common stock par value share share authorize december december share issue outstanding december december additional paidin capital accumulate comprehensive income retain earning total gilead stockholder equity noncontrolle interest total stockholder equity total liability stockholder equity accompany note gilead sciences inc consolidated statement income million share amount year end december revenue product sale royalty contract revenue total revenue cost expense cost good sell research development expense sell general administrative expense total cost expense income operation interest expense income expense net income provision income taxis provision income taxis net income net loss attributable noncontrolle interest net income attributable gilead net income share attributable gilead common stockholder basic share share calculation basic net income share attributable gilead common stockholder dilute share share calculation dilute cash dividend declare share accompany note gilead sciences inc consolidated statement comprehensive income million year end december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale security net unrealize gain loss net tax impact reclassification net income net tax impact net change cash flow hedge net unrealized gain loss net tax impact reclassification net income net tax impact net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolle interest comprehensive income attributable gilead accompany note gilead sciences inc consolidated statement stockholder equity millions gilead stockholder equity common stock accumulate additional total paidin comprehensive retain noncontrolle stockholder share capital income loss earning interest equity balance december contribution noncontrolle interest net income loss comprehensive loss net tax issuance employee stock purchase plan issuance equity incentive plan tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible notes hedge settlement reclassification equity component currently redeemable convertible note balance december change noncontrolle interest net income loss comprehensive income net tax issuance employee stock purchase plan issuance equity incentive plan tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible note hedge settlement purchase convertible note hedge reclassification equity component currently redeemable convertible note balance december change noncontrolle interest net income loss comprehensive loss net tax issuance employee stock purchase plan issuance equity incentive plans tax benefit employee stock plan stockbase compensation repurchase common stock warrant settlement convertible note settlement convertible note hedge settlement dividend declare reclassification equity component currently redeemable convertible note balance december accompany note gilead sciences inc consolidated statement cash flow millions year end december operating activity net income adjustment reconcile net income net cash provide operating activity depreciation expense amortization expense stockbase compensation expense excess tax benefit stockbase compensation tax benefit exercise vest stockbased award defer income taxis change operate asset liability account receivable net inventory prepaid expense asset account payable income taxis payable accrue liability defer revenue net cash provide operating activity invest activity purchase marketable security proceed sale marketable security proceed maturitie marketable security investment acquisition net cash acquire capital expenditure net cash investing activity financing activity proceed debt finance net issuance cost proceed convertible note hedge purchase convertible note hedge proceed issuance common stock repurchase common stock repayment debt obligation payment settle warrant excess tax benefit stockbase compensation payment contingent consideration payment dividend contribution noncontrolle interest net cash financing activity effect exchange rate change cash cash equivalent net change cash cash equivalent cash cash equivalent begin period cash cash equivalent end period supplemental disclosure cash flow information interest pay net amount capitalize income taxis pay accompany note gilead sciences inc note consolidated financial statement organization summary significant accounting policy overview gilead sciences inc gilead incorporate delaware june researchbase biopharmaceutical company discover develop commercialize innovative medicine area unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatene illness world gilead primary area focus include human immunodeficiency virus hiv liver disease chronic hepatitis c virus hcv infection chronic hepatitis b virus hbv infection cardiovascular hematologyoncology inflammationrespiratory operation country worldwide headquarters foster city california continue add exist portfolio product internal discovery clinical development program product acquisition inlicense strategy portfolio market product include ambisome atripla cayston compleraeviplera emtriva genvoya harvoni hepsera letairis ranexa sovaldi stribild tamiflu truvada tybost viread vitekta zydelig international commercial sale operation marketing subsidiary north south america europe asiapacific sell distribute certain product corporate partner royaltypaye collaborative agreement basis presentation accompany consolidated financial statement include account gilead whollyowne subsidiary certain variable interest entity primary beneficiary intercompany transaction eliminate consolidated entity expose economic record net income loss attributable noncontrolle interest consolidate statement income equal percentage economic ownership interest retain entity respective noncontrolle party assess primary beneficiary variable interest entity vie inception arrangement reporting date assessment base power direct activity vie significantly impact vie economic performance obligation absorb loss right receive benefit vie potentially significant vie december material vie joint venture bristolmyer squibb bms describe note collaborative arrangement significant accounting policy estimate judgment preparation consolidated financial statement require estimate judgment affect report amount asset liability revenue expense related disclosure ongoing basis evaluate significant accounting policy estimate base estimate historical experience market specific relevant assumption believe reasonable circumstance result form basis make judgment carry value asset liability readily apparent source actual result differ significantly estimate revenue recognition product sale recognize revenue product sale persuasive evidence arrangement exist delivery occur price fix determinable collectability reasonably assure recognition revenue product sale provision government rebate medicaid reimbursement customer incentive cash discount prompt payment distributor fee expect return expire product appropriate item deduct gross product sale rebate chargeback estimate reduction revenue amount pay payer healthcare providers united states include medicaid rebate adap veterans administration public health service discount rebate foreign government rebate rebate chargeback base contractual arrangement statutory requirement vary product payer individual payer plan estimate base product sell historical utilization rate available pertinent party industry information estimate patient population know market event trend product sale channel inventory datum obtain major wholesaler accordance inventory management agreement consideration available new information change program regulation guideline impact actual rebate andor expectation future utilization rate program government chargeback payable direct customer classify reduction account receivable consolidated balance sheet government rebate invoice directly record accrue government rebate consolidated balance sheet cash discount estimate cash discount base contractual term historical utilization rate available expectation future utilization rate distributor fee inventory management agreement significant wholesaler pay wholesaler fee primarily compliance certain contractually determine covenant maintenance agree inventory level distributor fee base contractually determine fix percentage sale product return provide customer general right product return typically permit return product damage defective receive customer case product sell united states certain country outside united states product expire accept return product expire month expire year expiration date estimate expect return expire product base primarily ongoing analysis historical return pattern historical industry information report return rate similar product contractual agreement intend limit inventory maintain wholesaler royalty contract revenue royalty revenue sale product generally recognize receive generally quarter follow quarter correspond sale occur month follow month correspond sale occur revenue nonrefundable upfront license fee milestone payment development collaboration obligation supply product recognize performance occur obligation complete accordance specific term obligation arrangement revenue recognize obligation fulfil ratably development manufacturing period revenue associate substantive atrisk milestone recognize base achievement milestone set forth respective agreement advance payment receive excess amount earn classified defer revenue consolidated balance sheet research development expense research development rd expense consist primarily personnel cost include salary benefit stockbase compensation clinical study perform contract research organization cro material supply license fee milestone payment collaboration arrangement overhead allocation consist support facilityrelate cost charge rd cost include clinical study cost expense incur clinical study cost significant component rd expense clinical study perform thirdparty cro monitor level performance significant contract include extent patient enrollment activity communication cro accrue cost clinical study perform cro service period specify contract adjust estimate require base ongoing review level effort cost actually incur cro material cro contract terminable write notice generally liable actual service complete cro certain noncancelable expense incur point termination advertising expense expense cost advertising include promotional expense incur advertising expense million million million cash cash equivalent consider highly liquid investment insignificant interest rate risk original maturity month purchase date cash equivalent eligible instrument investment policy include cash equivalent primarily include commercial paper money market fund overnight repurchase agreement repos major bank authorize dealer bank obligation marketable nonmarketable security determine appropriate classification marketable security consist primarily debt security time purchase reevaluate designation balance sheet date marketable security consider availableforsale carry estimate fair value report cash equivalent shortterm marketable security longterm marketable security unrealize gain loss availableforsale security exclude net income report accumulate comprehensive income loss separate component stockholder equity income expense net include interest dividend amortization purchase premium discount realize gain loss sale security otherthantemporary decline fair value security cost security sell base specific identification method regularly review investment otherthan temporary decline fair value review include consideration cause impairment include creditworthiness security issuer number security unrealize loss position severity duration unrealize loss intent sell security likely require sell security recovery amortize cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carry value security hold record loss decline result enter collaboration time time hold investment nonpublic company record nonmarketable security cost longterm asset amount otherthantemporary impairment regularly review security indicator impairment investment nonmarketable security material period present concentration risk subject credit risk portfolio cash equivalent marketable security investment policy limit amount invest security credit rating maturity industry group investment type issuer security issue government expose significant concentration credit risk financial instrument goal investment policy order priority follow safety preservation principal diversification risk liquidity investment sufficient meet cash flow requirement competitive aftertax rate return subject credit risk account receivable relate product sale majority trade account receivable arise product sale united states europe december account receivable southern europe specifically greece italy portugal spain total approximately billion million great day past include million great day past date experience significant loss respect collection account receivable certain raw material component utilize operation obtain single supplier certain raw material utilize operation facility supplier key component raw material name new drug application nda file food drug administration fda product significant delay occur qualification new supplier require delivery material supplier interrupt reason unable ship commercial product supply product candidate clinical trial account receivable trade account receivable record net allowance wholesaler chargeback relate government program cash discount prompt payment doubtful account estimate wholesaler chargeback government program cash discount base contractual term historical trend expectation utilization rate program estimate allowance doubtful account determine base exist contractual payment term historical payment pattern customer individual customer circumstance analysis day sale outstanding geographic region review local economic environment potential impact government funding reimbursement practice historically amount uncollectible account receivable write insignificant consistent management expectation inventory inventory record low cost market cost determine firstin firstout basis periodically review composition inventory order identify obsolete slowmoving unsaleable item unsaleable item observe alternate use inventory record writedown net realizable value period impairment recognize future commercialization consider probable future economic benefit expect realize base management judgment capitalize prelaunch inventory cost prior regulatory approval number factor take consideration include current status regulatory approval process potential impediment approval process safety efficacy anticipate research development initiative impact indication compound viability commercialization marketplace trend december prelaunch inventory consolidate balance sheet significant property plant equipment property plant equipment state cost accumulate depreciation amortization depreciation amortization recognize straight line method repair maintenance cost expense incur estimate useful life year generally follow description estimate useful life building improvement laboratory manufacturing equipment office computer equipment leasehold improvement short useful life lease term office computer equipment include capitalize software unamortize capitalize software cost consolidate balance sheet million december million december capitalize interest construction inprogress include property plant equipment interest capitalize significant goodwill intangible asset goodwill represent excess consideration transfer estimate fair value asset acquire liability assume business combination intangible asset indefinite useful life relate purchase inprocess research development iprd project measure respective fair value acquisition date amortize goodwill intangible asset indefinite useful live intangible asset relate iprd project consider indefinitelive completion abandonment associate rd effort development complete generally occur regulatory approval market product obtain associate asset deem finitelive amortize base respective estimate useful life point time test goodwill indefinitelive intangible asset impairment annual basis annual test aware event change indicate fair value asset carry amount intangible asset finite useful life amortize estimate useful life primarily straightline basis review impairment fact circumstance suggest carry value asset recoverable impairment longlive asset longlive asset include property plant equipment finitelive intangible asset review impairment regular basis fact circumstance internally externally suggest carry value asset asset group recoverable indication impairment test recoverability compare estimate undiscounted future cash flow expect result use asset asset group eventual disposition carry asset asset group excess carrying value asset asset group estimate fair value recognize impairment loss foreign currency translation transaction gain loss hedge contract nonus entity operation record functional currency entity result operation nonus dollar functional currency entity translate dollar average currency rate asset liability translate currency rate period end foreign currency translation adjustment record component comprehensive income loss stockholder equity foreign currency transaction gain loss record income expense net consolidated statement income net foreign currency transaction gain loss immaterial year end december hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose hedge net investment foreign subsidiary fair value financial instrument apply fair value account financial asset liability nonfinancial asset liability recognize disclose fair value financial statement recur basis define fair value price receive sell asset pay transfer liability orderly transaction market participant measurement date determine fair value measurement asset liability require record fair value consider principal advantageous market transact marketbase risk measurement assumption market participant use price asset liability risk inherent valuation technique transfer restriction credit risk derivative financial instrument recognize derivative instrument asset liabilitie fair value consolidate balance sheet change fair value derivative record period current earning accumulate comprehensive income loss depend derivative designate hedge transaction type hedge transaction classify cash flow instrument category cash flow hedge item hold issue derivative instrument trade speculative purpose assess inception ongoing basis derivative hedging transaction highly effective offset change cash flow fair value hedge item assess hedge ineffectiveness quarterly basis record gain loss relate ineffective portion current earning extent significant determine forecast transaction long probable occur discontinue hedge accounting affect portion hedge instrument relate unrealized gain loss contract recognize current earning income taxis income tax provision compute liability method defer tax asset liability determine base difference financial statement tax basis asset liability enact tax rate effect year difference expect reverse significant estimate require determine provision income taxis estimate base interpretation exist tax law regulation record liability relate uncertain tax position accordance guidance clarifie accounting uncertainty income taxis recognize enterprise financial statement prescribe minimum recognition threshold measurement attribute financial statement recognition measurement tax position take expect take tax return believe uncertain tax position currently pende material adverse effect consolidated financial statement adverse resolution uncertain tax position period material impact result operation period brand prescription drug bpd fee pharmaceutical manufacturer brand drug product require pay portion bpd fee calculate base select government sale calendar year percentage total industry government sale internal revenue service irs issue final regulation relate bpd fee accelerate expense recognition criterion fee obligation year fee pay year relate sale market share allocate fee determine bpd fee expense million million million record sell general administrative sga expense consolidated statement income bpd fee accrual total million december million december consolidated balance sheet recent accounting pronouncement financial accounting standard board fasb jointly international accounting standard board issue comprehensive new standard revenue recognition contract customer standard core principle report entity recognize revenue transfer promise good service customer reflect consideration entity expect entitled exchange good service august fasb issue accounting standard update defer effective date new standard year standard effective begin quarter early adoption permit entity option retrospective modify retrospective approach adopt new guidance evaluate impact adoption standard consolidated financial statement april fasb issue accounting standard update require presentation debt issuance cost direct deduction carrying recognize debt liability balance sheet update change guidance recognition measurement debt issuance cost guidance effective begin quarter time adoption reclassify debt issuance cost liability direct deduction carry value debt consistent presentation debt discount expect adoption update material impact consolidated balance sheet november fasb issue accounting standard update require defer tax liability asset classify noncurrent balance sheet previous guidance require defer tax liability asset separate current noncurrent amount balance sheet guidance effective begin quarter apply prospectively retrospectively early adoption permit time adoption reclassify current defer tax amount consolidate balance sheet noncurrent evaluate impact method adoption standard consolidated financial statement january fasb issue new guidance relate accounting equity investment financial liability fair value option presentation disclosure requirement financial instrument addition fasb clarify guidance relate valuation allowance assessment recognize defer tax asset result unrealized loss availableforsale debt security guidance effective begin quarter early adoption permit evaluate impact adopt accounting guidance consolidated financial statement fair value measurement determine fair value financial nonfinancial asset liability fair value hierarchy establish level input measure fair value follow level input include quote price active market identical asset liability level input include observable input level input quote price similar asset liability quote price identical similar asset liability market active input observable corroborate observable market datum substantially term asset liability marketable security review trading activity pricing measurement date sufficient quote price identical security available use market pricing observable market input similar security obtain thirdparty datum provider input represent quote price similar asset active market derive observable market datum level input include unobservable input support little market activity significant fair value underlie asset liability level asset liability include fair value measurement determine pricing model discount cash flow methodology similar valuation technique significant management judgment estimation financial instrument consist principally cash cash equivalent marketable security account receivable foreign currency exchange contract account payable shortterm longterm debt cash cash equivalent marketable security foreign currency exchange contract hedge account receivable forecast sale report respective fair value consolidate balance sheet shortterm longterm debt report amortize cost consolidated balance sheet remain financial instrument report consolidated balance sheet amount approximate current fair value transfer fair value level period present follow table summarize asset liability measure fair value recur basis level fair value hierarchy million december december level level level total level level level total asset money market fund corporate debt security treasury security residential mortgage assetbacke security government agency security certificate deposit nonus government security municipal debt security foreign currency derivative contract defer compensation plan liabilitie contingent consideration defer compensation plan foreign currency derivative contract level input estimate fair value investment corporate debt security residential mortgage assetbacked security governmentrelate security certificate deposit take consideration valuation obtain thirdparty pricing service pricing service utilize industry standard valuation model include income marketbase approach significant input observable directly indirectly estimate fair value input include report trade brokerdealer quote similar security issuer credit spread benchmark security prepaymentdefault projection base historical datum observable input substantially foreign currency derivative contract maturity month time horizon counterpartie minimum credit rating equivalent standard poor moody investors service inc fitch inc estimate fair value contract take consideration valuation obtain thirdparty valuation service utilize incomebase industry standard valuation model significant input observable directly indirectly input include foreign currency rate london interbank offer rate libor swap rate input applicable commonly quote interval total estimate fair value convertible senior note senior unsecured note determine level input base quote market value approximately billion december billion december carry value billion december billion december level input december asset liability measure level input contingent consideration liability policy recognize transfer level classification actual date event change circumstance cause transfer contingent consideration liability immaterial december availableforsale security estimate fair value availableforsale security generally base price obtain commercial pricing service follow table summary availableforsale security record cash cash equivalent marketable security consolidate balance sheet million december december gross gross gross gross amortize unrealize unrealized estimate amortize unrealize unrealized estimate cost gain loss fair value cost gain loss fair value money market fund corporate debt security treasury security residential mortgage asset back security government agency security certificate deposit nonus government security municipal debt security total follow table summarize classification availableforsale security consolidate balance sheet million december december cash cash equivalent shortterm marketable security longterm marketable security total cash cash equivalent table exclude cash billion december billion december follow table summarize portfolio availableforsale security contractual maturity million december amortize cost fair value year great year year great year year great year total follow table summarize availableforsale debt security continuous unrealized loss position deem otherthan temporarily impair million month month great total gross gross gross unrealize estimate unrealized estimate unrealized estimate loss fair value loss fair value loss fair value december debt security corporate debt security treasury security residential mortgage assetbacke security government agency security nonus government security municipal debt security total december debt security corporate debt security residential mortgage assetbacke security treasury security government agency security municipal debt security total hold total position december position december unrealize loss position base review security believe otherthantemporary impairment security december intend sell security believe likely require sell security recovery amortize cost basis gross realize gain gross realize loss immaterial year end december derivative financial instrument operation foreign country expose market risk associate foreign currency exchange rate fluctuation dollar foreign currency significant euro yen order manage risk hedge portion foreign currency exposure related outstanding monetary asset liability forecast product sale foreign currency exchange forward option contract general market risk relate contract offset correspond gain loss hedge transaction credit risk associate contract drive change interest currency exchange rate result vary time work major bank closely monitor current market condition seek limit risk counterpartie contract unable perform seek limit risk loss enter contract permit net settlement maturity overall risk loss event counterparty default limit unrecognized gain outstanding contract ie contract positive fair value date default enter derivative contract trading purpose hedge exposure foreign currency exchange rate fluctuation certain monetary asset liability entity denominate non functional currency derivative instrument use hedge exposure designate hedge result change fair value record income expense net consolidated statement income hedge exposure foreign currency exchange rate fluctuation forecast product sale denominate nonfunctional currency derivative instrument use hedge exposure designate cash flow hedge maturity date month execute hedge contract quarterly assess prospective hedge effectiveness regression analysis calculate change cash flow result hedge instrument quarterly basis assess retrospective hedge effectiveness dollar offset approach exclude time value effectiveness testing recognize change time value hedge income expense net effective component hedge record unrealized gain loss hedge instrument accumulate comprehensive income oci stockholder equity hedge forecast transaction occur hedge de designate unrealized gain loss reclassify product sale majority gain loss relate hedged forecast transaction report accumulate oci december expect reclassify product sale month cash flow effect derivative contract year end december include net cash provide operating activity consolidate statement cash flow notional amount foreign currency exchange contract outstanding billion december billion december derivative contract allow right offset asset liability present amount gross basis international swap dealers association inc master agreement respective counterpartie foreign currency exchange contract subject applicable requirement allow net settle transaction currency single net payable party follow table summarize classification fair value derivative instrument consolidate balance sheet million december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative designate hedge derivative designate hedge foreign currency exchange contract current asset accrue liability total derivative designate hedge total derivative december asset derivative liability derivative fair classification fair value classification value derivative designate hedge foreign currency exchange contract current asset accrue liability foreign currency exchange contract longterm asset longterm obligation total derivative december material derivative designate hedge follow table summarize effect foreign currency exchange contract consolidate financial statement millions year end december derivative designate hedge gain loss recognize accumulate oci effective portion gain loss reclassify accumulated oci product sale effective portion gain loss recognize income expense net ineffective portion amount exclude effectiveness testing derivative designate hedge gain loss recognize income expense net time time discontinue cash flow hedge result record relate amount income expense net consolidated statement income material amount record income expense net year end december result discontinuance cash flow hedge december hold type financial instrument derivative contract relate foreign currency exchange contract follow table summarize potential effect offset derivative type financial instrument consolidated balance sheet million december offset derivative assetsliabilitie gross amount offset consolidated balance sheet amount assetsliabilitie gross amount offset present gross amount consolidate balance consolidate derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability december offset derivative assetsliabilitie gross amount offset consolidated balance sheet gross amount offset amount assetsliabilitie gross amount consolidated balance present consolidated derivative financial cash collateral net description recognize assetsliabilitie sheet balance sheet instrument receivedpledge legal offset derivative asset derivative liability inventory inventory summarize follow million december raw material work process finish good total report inventory longterm asset total amount report longterm asset primarily consist raw material december december joint venture form gilead sciences llc bms note collaborative arrangement include consolidated financial statement hold efavirenz active pharmaceutical ingredient inventory efavirenz inventory purchase bms bms estimate net selling price efavirenz total billion december million december property plant equipment property plant equipment summarize follow million december building improvement include leasehold improvement laboratory manufacturing equipment office computer equipment construction progress subtotal accumulate depreciation amortization include related capitalize lease equipment subtotal land total intangible asset follow table summarize carry intangible asset million december finitelive intangible asset indefinitelive intangible asset total intangible asset finitelive intangible asset follow table summarize finitelive intangible asset millions december december gross carry accumulate gross carry accumulate amortization amortization intangible asset sofosbuvir intangible asset ranexa total amortization expense relate finitelived intangible asset include primarily cost good sell consolidated statement income total million million million december estimate future amortization expense associate finitelive intangible asset succeed fiscal year follow millions fiscal year total indefinitelive intangible asset complete acquisition ym biosciences ym total million fair value acquire asset assume liability ym attribute million iprd relate momelotinib consolidated balance sheet follow table summarize indefinitelive intangible asset december december millions indefinitelive intangible asset momelotinib indefinitelive intangible asset total financial information prepay current asset component prepay current asset summarize follow million december prepay taxis prepaid expense current asset total prepay current asset accrue liability component accrue liability summarize follow million december income taxis payable compensation employee benefit brand prescription drug fee accrue royalty accrue expense total accrue liability collaborative arrangement enter collaborative arrangement party development commercialization certain product party active participant operating activity collaboration expose significant risk reward depend commercial success activity follow significant collaborative arrangement bristolmyers squibb company north america enter collaboration arrangement bms develop commercialize single tablet regimen contain truvada bms sustiva efavirenz united states combination approve use united states sell brand atripla bms structure collaboration joint venture operate limited liability company name bristolmyers squibb gilead sciences llc consolidate bms grant royaltyfree sublicense joint venture use respective company own technology return grant license joint venture use intellectual property result collaboration bms amend joint venture collaboration agreement allow joint venture sell atripla canada economic interest joint venture hold bms include share revenue outofpocket expense base portion net selling price atripla attributable efavirenz truvada net selling price truvada change time relative net selling price efavirenz bms respective economic interest joint venture vary annually bms share marketing sale effort start second quarter limited number activity jointly manage party long coordinate detail promotional activity united states party reduce joint promotional effort launch complera august stribild august party continue collaborate activity manufacture regulatory compliance pharmacovigilance daily operation joint venture govern primary joint committee form bms gilead responsible accounting financial reporting tax reporting manufacturing product distribution joint venture party provide respective bulk active pharmaceutical ingredient joint venture approximate market value agreement continue terminate mutual agreement party addition party terminate party participation collaboration day launch generic version party single agent product double agent product terminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination december joint venture hold efavirenz active pharmaceutical ingredient purchase bms bms estimate net selling price efavirenz market amount primarily include inventory consolidate balance sheet select financial information joint venture follow million december total asset cash cash equivalent account receivable net inventory total liability account payable accrue liability asset liability amount reflect impact intercompany elimination include consolidated balance sheet consolidate joint venture legal structure joint venture limit recourse creditor general credit asset similarly asset hold joint venture settle obligation joint venture europe gilead sciences ireland uc whollyowne subsidiary bms enter collaboration agreement bms set forth term condition bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory party form limited liability company consolidate manufacture atripla distribution european territory efavirenz purchase bms bms estimate net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehouse local subsidiary primary responsibility order fulfillment collection receivables customer relation handle sale return territory bms promote atripla general party share revenue outofpocket expense proportion net selling price component atripla truvada efavirenz start limited number activity jointly manage party long coordinate detail promotional activity region responsible accounting financial reporting tax reporting collaboration december efavirenz purchase bms bms estimate net selling price efavirenz european territory include inventory consolidate balance sheet party form limited liability company hold marketing authorization atripla europe primary responsibility regulatory activity major market country party agree independently continue use commercially reasonable effort promote atripla agreement terminate expiration lasttoexpire patent afford market exclusivity atripla component european territory addition december party terminate agreement reason termination effective calendar quarter notice termination nonterminate party right continue sell atripla continue party obligate pay terminate party certain royalty threeyear period follow effective date termination event continue party decide sell atripla effective date termination date atripla withdraw country date party assume distribution atripla whichever early japan tobacco inc japan tobacco inc japan tobacco grant exclusive right develop commercialize elvitegravir novel hiv integrase inhibitor country world exclude japan japan tobacco retain right agreement responsible seek regulatory approval territory require use diligent effort commercialize elvitegravir treatment hiv infection bear cost expense associate commercialization effort receive approval stribild elvitegravircontaine product fda august european commission receive approval genvoya elvitegravircontaine product fda european commission november agreement obligation pay royalty japan tobacco terminate productbyproduct basis patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement reason case license grant japan tobacco terminate party terminate agreement response material breach party janssen enter license collaboration agreement janssen sciences ireland uc janssen tibotec pharmaceutical develop commercialize fixeddose combination truvada janssen nonnucleoside reverse transcriptase inhibitor rilpivirine combination approve united states european union sell brand complera united states eviplera european union original agreement janssen grant exclusive license compleraeviplera worldwide exclude certain middle income develop world country japan amend agreement include distribution compleraeviplera rest world amend agreement expand collaboration include product contain janssen rilpivirine emtricitabine tenofovir alafenamide rftaf amend agreement janssen grant exclusive license compleraeviplera rftaf worldwide retain right distribute combination product country include mexico russia japan party restrict combine drug drug product similar component compleraeviplera rftaf responsible manufacturing compleraeviplera rftaf lead role registration distribution commercialization product country janssen distribute janssen exercise right codetail combination product country gilead sell party initial agreement price compleraeviplera expect sum price truvada price rilpivirine purchase separately cost rilpivirine purchase janssen compleraeviplera approximately market price rilpivirine specified percentage major market amendment effective enable sell party set price combine product party share revenue base ratio net selling price party component subject certain restriction adjustment continue retain specify percentage janssen share revenue major market party terminate collaboration agreement respect product country product withdraw market country respect product country party materially breach agreement respect product agreement party obligation share revenue expire productbyproduct countrybycountry basis janssen patent provide exclusivity product expire later tenth anniversary commercial launch product terminate agreement cause respect country sell product case janssen right sell party country product launch market few year debt credit facility financing arrangement follow table summarize carry borrowing financing arrangement millions state december type borrowing issue date date interest rate convertible senior july senior unsecured december december senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september september senior unsecured march april senior unsecured december december senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september september senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march total debt net current portion total longterm debt net senior unsecured note issue billion aggregate principal senior unsecured note note register offering issue billion aggregate principal senior unsecured note note register offering march november notes note issue general corporate purpose include repayment debt work capital payment dividend repurchase outstanding common stock pursuant authorize share repurchase program collectively refer note note senior unsecured note issue march december note senior note senior note redeem option redemption price equal great principal note redeem ii sum determine independent investment banker present value remain schedule payment principal interest note redeem exclusive interest accrue date redemption discount redemption date semiannual basis treasury rate plus makewhole premium define indenture senior note mature feature exercisable option redeem note par month immediately precede maturity case accrue unpaid interest require redeem date redemption repay maturity million principal balance relate note event occurrence change control downgrade rate senior note investment grade standard poor rating service moody investors service inc holder require purchase portion senior note price equal aggregate principal note repurchase plus accrue unpaid interest date repurchase incur debt issuance cost million connection issuance note million note amortize interest expense contractual term respective note recognize million million million interest expense senior note relate contractual coupon rate amortization debt discount issuance cost convertible senior note july issue billion convertible senior note note billion convertible senior note note collectively note note private placement pursuant rule securities act amend note issue par note bore annual interest rate note bear annual interest rate debt issuance cost million record long term asset amortize interest expense contractual term note initial conversion rate note share principal represent initial conversion price approximately share initial conversion rate note share principal represent initial conversion price approximately share conversion rate subject customary antidilution adjustment include quarterly dividend distribution december conversion rate note represent conversion price approximately share note convert prior april follow circumstance calendar quarter commence september closing price common stock trading day consecutive period consecutive trading day end trading day precede calendar quarter great applicable conversion price applicable trading day business day period measurement period consecutive trading day trading day period trading price principal note product report sale price common stock applicable conversion rate trading day occurrence specify corporate transaction distribution certain stock right cash amount asset shareholder occurrence change control april case note holder convert note time regardless forego circumstance generally conversion holder receive cash equal less principal note ii conversion value note measure indenture govern relevant note conversion value exceed principal deliver option cash common stock combination cash common stock conversion value excess principal portion note convert note mature portion note convert follow table summarize information note settlement million conversion value pay excess net proceed convertible note principal repayment principal hedge year end december year end december year end december note december give maturity date note classified current december note classify current give conversion criterion meet result related equity component equal unamortized discount million million december respectively classified equity component currently redeemable convertible note consolidated balance sheet note convert connection change control require provide premium form increase conversion rate subject state maximum addition event change control holder require purchase portion note purchase price equal principal plus accrue unpaid interest december ifconverte value note exceed principal amount note billion concurrent issuance note purchase convertible note hedge private transaction cost million tax deductible life note sell warrant private transaction acquire million share common stock receive net proceed million sale warrant convertible note hedge warrant intend reduce potential economic dilution future conversion note effectively increase conversion price share note share note net cost million convertible note hedge warrant transaction record stockholder equity consolidated balance sheet addition contract classify stockholder equity index common stock account derivative convertible note hedge cover subject customary antidilution adjustment million share common stock strike price initially correspond initial conversion price note subject adjustment similar applicable conversion price relate note market value share common stock time conversion note strike price applicable convertible note hedge entitle receive counterpartie transaction share common stock extent correspond election respect relate convertible note cash combination cash share common stock option excess market value common stock strike price convertible note hedge convertible note hedge terminate maturity note note remain outstanding conversion million share common stock underlie warrant subject customary antidilution adjustment warrant strike price share warrant expire warrant share warrant expire warrant warrant warrant term exercisable respective expiration date market value common stock time exercise applicable warrant exceed respective strike price require net settle cash share common stock option respective counterpartie value warrant excess warrant strike price enter modify agreement warrant counterpartie change time expiration million warrant modify agreement allow settle million warrant option cash share accord term modify agreement warrant expire tradingday period commence end june exercise option settle cash result pay billion market value common stock time exercise warrant exceed strike price warrant settle option cash share common stock original modify agreement contract meet applicable criterion equity classification settlement payment record reduction paidin capital consolidate balance sheet remainder allocate retain earning extent additional paidin capital reduce zero december million warrant remain outstanding strike price share adjust quarterly dividend distribution expire tradingday period commencing august change term remain million warrant exercise option settle warrant cash result pay billion settle warrant market value common stock time exercise warrant exceed strike price million share common stock underlie warrant strike price share expire tradingday period commence august end september warrant settle option cash share common stock relate contract meet applicable criterion equity classification settlement record reduction additional paidin capital consolidate balance sheet current accounting guidance bifurcated conversion option note debt instrument classified conversion option equity accrete result debt discount interest expense contractual term note follow table summarize information equity liability component note million carry value net carrying unamortized discount equity component liability component liability component december december december note recognize interest expense million million million relate contractual coupon rate amortization debt discount issuance cost note effective interest rate liability component note note respectively credit facility january enter fiveyear billion revolve credit facility credit agreement fiveyear revolve credit agreement expire january borrow million thereunder repay million fiveyear revolve credit agreement repay remain balance million outstanding fiveyear revolve credit agreement contain customary representation warranty affirmative negative financial maintenance covenant event default loan bear interest eurodollar rate plus applicable margin ii base rate plus applicable margin define credit agreement reduce commitment prepay loan time premium penalty fiveyear revolve credit agreement terminate amount owe agreement shall payable january amount outstanding credit agreement december december require comply certain covenant credit agreement note indenture december violation covenant contractual maturity finance obligation december aggregate future principal maturity finance obligation year base contractual date follow million year contractual maturity commitment contingency lease arrangement lease facility equipment relate primarily administrative rd sale marketing activity longterm noncancelable operating lease united states international market lease expire date lease contain option renew lease expense operating lease approximately million million million aggregate noncancelable future minimum rental payment operating lease follow million total legal proceeding party legal action significant describe possible determine outcome matter reasonably estimate maximum potential exposure range possible loss litigation relate sofosbuvir january acquire pharmasset inc pharmasset acquisition acquire sofosbuvir nucleotide analog act inhibit replication hepatitis c virus hcv december receive food drug administration fda approval sofosbuvir know commercially sovaldi october receive approval fixeddose combination ledipasvir sofosbuvir ldvsof know commercially harvoni receive number contractual intellectual property claim sofosbuvir carefully consider claim prior follow acquisition believe merit predict ultimate outcome claim range loss patent patent application claim sofosbuvir sovaldi chemical entity metabolite fixeddose combination ledipasvir sofosbuvir harvoni party obtain right patent allegedly prevent attempt prevent commercialize sovaldi harvoni example aware patent patent application own party future allege party cover use sovaldi harvoni predict ultimate outcome intellectual property claim relate sovaldi harvoni spend continue spend significant resource defend claim party successfully obtain valid enforceable patent successfully prove infringement patent sovaldi andor harvoni prevent sell product able obtain license patent license available commercially reasonable term interference proceeding litigation idenix pharmaceuticals inc idenix february receive notice patent trademark office uspto declare interference idenix interference patent patent idenix pende patent application interference proceed uspto design determine invent subject matter claim party january uspto patent trial appeal board ptab determine pharmasset idenix invent compound dispute accordingly gilead prevail idenix interference idenix appeal ptab decision district court district delaware december receive request uspto declare interference second idenix interference pende patent application idenixs patent patent patent relate idenix patent application issue idenix interference include claim direct method treat hcv nucleoside compound purpose second idenix interference determine invent claim method treat hcv compound similar involved idenix interference march ptab determine pharmasset idenix invent claim method treat hcv idenix appeal decision district court district delaware court appeal federal circuit cafc file motion dismiss appeal delaware respond appeal file cafc believe idenix claim involve second idenix interference similar foreign patent claim compound metabolite use thereof invalid result file impeachment action federal court canada invalidate idenix canadian patent patent canadian patent correspond patent idenix assert commercialization sovaldi canada infringe patent canadian patent correspond patent involve idenix interference invalid trial issue hold january february november federal court canada render public decision hold idenix patent invalid gilead patent valid month idenix appeal court decision file similar legal action norway oslo district court seek invalidate idenix norwegian patent correspond patent september idenix file invalidation action norwegian proceeding norwegian patent patent correspond gilead patent march norwegian court find claim idenix norwegian patent invalid upheld validity claim challenge gilead patent april idenix appeal march decision norwegian court appeal appeal hear march decision take place february january file legal action federal court australia seek invalidate idenixs australian patent correspond patent april idenix assert commercialization sovaldi australia infringe australian patent correspond patent monthlong trial complete october sydney decision pende march european patent office epo grant idenix european patent patent correspond patent day patent grant file opposition epo seek revoke patent opposition hearing hold february epo rule favor revoke patent march idenix initiate infringement proceeding united kingdom uk germany france allege commercialization sovaldi infringe uk german french counterpart patent trial hold uk october determine issue infringement validity idenix uk patent december high court justice england wale uk court invalidate challenge claim patent multiple ground uk court grant idenix permission appeal december judgment appeal uk court decision schedule july march german court dsseldorf determine idenix patent highly likely invalid stay infringement proceeding pende outcome opposition hearing hold epo february idenix appeal decision german court staying proceeding idenix request french proceeding stay idenix award patent correspond patent japan china event patent issue expect challenge proceeding similar invoke country december idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversit montpellier ii sue district court district delaware allege commercialization sofosbuvir infringe patent interference exist patent patent december idenix udsg sue district court district massachusetts allege commercialization sofosbuvir infringe patent nos june court transfer massachusetts litigation district court district delaware district court set trial date october december resolution issue decision district court appeal party cafc idenix acquire merck august acquisition change view lack merit claim idenix merck great resource idenix choose fund litigation high level idenix litigation merck august merck contact request pay royalty sale sofosbuvir obtain license patent nos coown isis pharmaceuticals inc august file lawsuit district court northern district california seek declaratory judgment merck patent invalid infringe merck patent nos cover compound include relate sofosbuvir patent prosecution merck amend patent application attempt cover compound relate sofosbuvir court determine merck patent valid infringe claim require obtain license pay royalty merck commercialize sofosbuvir court set trial date march lawsuit party appeal decision district court cafc litigation abbvie inc abbvie abbvie obtain patent nos abbvie patent purport cover use combination ldvsof harvoni treatment hcv gilead aware abbvie pende patent application united states grant pende application country publish pende patent application direct use combination treatment hcv specifically combination ldvsof certain application file abbvie patent reason believe abbvie patent invalid accordingly december file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid unenforceable relief believe abbott laboratories inc abbvie conspire eliminate competition hcv market falsely represent uspto gilead invent method treat hcv combination ldvsof february march abbvie respond lawsuit file lawsuit district court district delaware allege fixeddose combination ldvsof infringe patent lawsuit consolidate single action united states party appeal decision district court cafc abbvie patent block delayed commercialization combination product united states canada europe expect foreign patent block delay commercialization world court set trial date september lawsuit additionally abbvie obtain patent purport cover solid oral dosage form contain ledipasvir accordingly file lawsuit district court district delaware seek declaratory judgment abbvie patent invalid relief expect abbvie patent block commercialization combination product court set trial date july august bring impeachment action seek declaration abbvie canadian patent patent purport cover use combination ldvsof treatment hcv invalid day abbvie bring infringement action assert commercialization harvoni canada infringe patent impeachment action stay counterclaimed invalidity infringement proceed trial date set november abbvie file lawsuit regional court dsseldorf infringement quasipatent know utility model utility model unexamine ip right standard patent utility model de purport cover use combination direct acting antiviral includes hcv polymerase inhibitor hcv nsa inhibitor treatment hcv utility model de purport cover solid dispersion include ledipasvir trial date set court determine abbvie patent valid infringe claim require obtain license pay royalties abbvie commercialize sofosbuvir combination product european patent claim february party file opposition european patent office request revocation grant european patent cover sofosbuvir expire confident strength sofosbuvir patent predict ultimate outcome opposition unsuccessful defend opposition patent claim narrowed revoke patent protection sofosbuvir europe substantially shorten eliminate entirely sofosbuvir patent revoke european patent grant cover sofosbuvir exclusivity base entirely regulatory exclusivity grant european medicine agency ema sovaldi grant regulatory exclusivity prevent generic sofosbuvir enter european union year follow approval sovaldi january lose exclusivity sovaldi prior expect revenue result operation negatively impact year include succeed year exclusivity lose cause stock price decline litigation generic manufacturer approval process product fda grant new chemical entity nce exclusivity period manufacturer application approval generic version product approve generic manufacturer challenge patent protect product grant nce exclusivity year prior end nce exclusivity period generic manufacturer seek continue seek fda approval similar identical drug abbreviate new drug application anda application form typically manufacturer seek approval generic drug sale generic version product early patent expiration significant negative effect revenue result operation current legal proceeding significance generic manufacturer include hiv product november december august receive notice teva pharmaceutical teva submit abbreviate new drug submission and canadian minister health request permission manufacture market generic version truvada atripla viread notice teva allege patent associate truvada atripla viread invalid unenforceable andor infringe teva manufacture use sale generic version product file lawsuit teva federal court canada seek order prohibition approval application december court issue order prohibit canadian minister health approving tevas generic version viread truvada atripla product expiry patent july teva appeal decision decision rule validity patent accordingly issue appeal minister health prohibit approve tevas product appeal hear canadian federal court appeal trial impeachment action court determine validity patent pende impeachment action trial impeachment action schedule november teva successful invalidating patent teva able launch generic version viread truvada atripla products canada prior expiry patent april july receive notices mylan inc mylan submit anda fda request permission manufacture market generic version truvada complera notice mylan allege patent associate truvada complera invalid unenforceable andor infringe mylan manufacture use sale generic version product file lawsuit mylan district court northern district west virginia infringement patent june receive notice mylan submit petition inter parte review ipr ptab allege patent associate tenofovir disoproxil fumarate invalid oppose mylan petition december ptab issue decision deny mylan petition ipr january mylan request rehear basis believe ptab decision wrong august november ptab deny mylan request rehear october reach agreement mylan settle proceeding term settlement agreement confidential june receive notice apotex inc apotex submit and canadian minister health request permission manufacture market generic version truvada separate and request permission manufacture market generic version viread notice apotex allege patent associate truvada patent associate viread invalid unenforceable andor infringe apotex manufacture use sale generic version truvada viread august file lawsuit apotex federal court canada seek order prohibition approval and hearing case schedule april letairis february receive notice watson laboratories inc watson submit anda fda request permission manufacture market generic version letairis notice watson allege patent associate ambrisentan tablet invalid unenforceable andor infringed watson manufacture use sale generic version letairis april file lawsuit watson district court district new jersey june receive notice sigmapharm laboratory llc sigmapharm submit anda fda request permission manufacture market generic version letairis notice sigmapharm allege patent associate ambrisentan tablet invalid unenforceable andor infringe sigmapharm manufacture use sale generic version letairis june file lawsuit sigmapharm district court district new jersey predict ultimate outcome action spend significant resource enforce defend patent unsuccessful lawsuit claim patent narrow invalidated patent protection product substantially shorten patent cover product invalidate fda health canada approve request manufacture generic version products united states canada respectively prior expiration date patent sale generic version product early patent expiration significant negative effect revenue result operation taf litigation january aids healthcare foundation inc ahf file complaint district court northern district california gilead japan tobacco inc japan tobacco international usa japan tobacco emory university emory ahf claim patent nos invalid usc et seq addition ahf claim gilead independently japan tobacco emory violate federal antitrust law market sale tenofovir alafenamide taf offer taf fixeddose combination product elvitegravir cobicistat emtricitabine ahf seek declaratory judgment invalidity patent monetary damage department justice investigation june receive subpoena attorney office northern district california request document relate manufacture relate quality distribution practice complera atripla truvada viread emtriva hepsera letairis cooperate government inquiry april united states department justice inform follow investigation decline intervene false claim act lawsuit file employee april employee serve amend complaint january federal district court issue order grant entirety prejudice motion dismiss amend complaint february plaintiff file second amend complaint june federal district court issue order grant motion dismiss second amend complaint july plaintiff file notice appeal court appeal ninth circuit matter party legal action arise ordinary course business believe legal action material adverse impact consolidate business financial position result operation commitment normal course business enter firm purchase commitment primarily relate active pharmaceutical ingredient certain inventory relate item december commitment year approximately billion million million million million amount relate active pharmaceutical ingredient represent minimum purchase commitment actual payment purchase relate active pharmaceutical ingredient billion billion billion enter letter credit bank guarantee support commercial activity outstanding letter credit bank guarantee total million december majority letter credit bank guarantee expire year expect funded stockholder equity stock repurchase programs january board director authorize fiveyear billion stock repurchase program program purchase program open market privately negotiate transaction program commence billion stock repurchase program authorize board director program complete quarter billion repurchase program authorize board director january program complete december remain authorize repurchase program billion follow table summarize stock repurchase abovedescribe program millions share datum year end december share repurchase retire average price share include million share repurchase billion program million share repurchase billion program include million share repurchase billion program million share repurchase billion program share repurchase program february enter accelerate share repurchase program asr repurchase billion common stock pay billion receive million share common stock represent approximately total share expect deliver asr total number share receive asr base average price common stock purchase period end april february board director authorize new billion share repurchase program program commence completion program purchase program open market privately negotiate transaction use par value method accounting stock repurchase par value method common stock charge par value share involve excess cost share acquire par value allocate additional paidin capital apic base estimate average sale price issue share excess amount charge retain earning addition repurchase stock repurchase program repurchase share common stock withhold employee restrict stock award satisfy applicable tax withholding obligation follow table summarize reduction common stock apic charge retain earning result stock repurchase millions year end december reduction common stock apic charge retain earning dividend second quarter begin pay quarterly dividend common stock follow table summarize cash dividend declare common stock million share datum dividend share second quarter quarter fourth quarter total restrict stock performancebase stock unit dividend equivalent right entitle holder dividend equivalent pay vest share underlie unit february announce board director declare quarterly cash dividend share common stock payment date march stockholders record close business march prefer stock million share authorize preferred stock issuable series board authorize determine designation power preference right series prefer stock outstanding december accumulate comprehensive income follow table summarize change accumulate oci component net tax million unrealize gain loss unrealize gain foreign currency availableforsale loss cash item security flow hedge total balance december comprehensive income loss reclassification amount reclassify accumulated comprehensive income net current period comprehensive income loss balance december comprehensive income loss reclassification amount reclassify accumulated comprehensive income net current period comprehensive income loss balance december amount reclassify gain loss cash flow hedge record product sale consolidate statement income amount reclassify gain loss availableforsale security record income expense net consolidated statement income employee benefit utilize share base compensation form type equitybase award include restrict stock unit rsus performancebase restrict stock unit psus stock option compensation expense recognize consolidated statement income base estimate fair value award grant date estimate fair value rsus base closing price common stock psus estimate fair value base monte carlo valuation methodology stock price date grant stock option award estimate fair value base blackschole option valuation model equity incentive plan stockholder approve adopt gilead sciences inc equity incentive plan plan plan broad base incentive plan provide grant equitybase award include stock option restrict stock unit restrict stock award performance award employee director consultant plan authorize issue maximum million share fullvalue award restrict stock restrict stock unit performance share performance unit extent settle common stock phantom share term plan plan authorize issuance total million share common stock december total million share remain available future grant plan stock option plan provide option grant designate nonqualifie incentive stock option prior january grant nonqualified incentive stock option stock option grant january nonqualified stock option plan employee stock option grant prior generally vest year stock option grant start generally vest year option exercisable period exceed contractual term year date stock option issue grant price fair market value common stock grant date stock option exercise settle common stock plan previously authorize available pool share follow table summarize activity relate information stock option plan option grant present table exercise price fair value underlie common stock grant date weight weightedaverage average remain share exercise price contractual term aggregate intrinsic thousand dollar year value millions outstanding december grant forfeit expired exercise outstanding december exercisable december expect vest net estimate forfeiture december aggregate intrinsic value represent value close stock price trading day year excess weightedaverage exercise price multiply number option outstanding exercisable total intrinsic value option exercise billion billion million weightedaverage grant date fair value stock option grant share share share december million unrecognized compensation cost relate stock option expect recognize estimate weightedaverage period year performancebase restrict stock unit plan grant psus vest achievement specify market performance goal include achieve total shareholder return compare predetermine peer group achieve revenue target actual number common share ultimately issue calculated multiplying number psus payout percentage range award generally vest committee subcommittee board determine specify market performance goal achieve fair value psu estimate date grant performance objective define grant depend term award fair value date grant determine base monte carlo valuation methodology closing stock price date grant addition grant psus certain employee plan vest award subject achievement specify individual performance goal typically year period fair value award equal closing price common stock grant date follow table summarize activity relate information psus weight average grantdate fair value share share thousand dollar outstanding december grant vest forfeited outstanding december weightedaverage grantdate fair value share exclude share relate grant currently grantdate fair value performance objective define weightedaverage grant date fair value psus grant share share share total grant date fair value vest psus million million million total fair value respective vest date million million million recognize stockbased compensation expense million million million related psus december million unrecognized compensation cost relate psus expect recognize estimate weightedaverage period year restrict stock unit grant timebase rsus certain employee annual employee equity compensation review program new hire employee nonemployee members board rsus share awards entitle holder receive freely tradable share common stock vest award grant prior employee rsus vest ratably annual basis year date grant start january rsus vest year date grant fair value rsu equal closing price common stock grant date follow table summarize rsu activity relate information weight average grantdate fair value share share thousand dollar outstanding december grant vest forfeited outstanding december weightedaverage grant date fair value rsus grant share share share total grant date fair value vest rsus million million million total fair value respective vest date million million million december million unrecognized compensation cost relate unvested rsus expect recognize weightedaverage period year employee stock purchase plan employee stock purchase plan international employee stock purchase plan amend espp employee purchase share common stock base percentage compensation subject certain limit purchase price share equal low fair market value common stock offering date purchase date prior espp offer twoyear lookback feature automatic reset feature provide offer period reset new lowerpriced offering offer price new offering period current offering period begin quarter lookback feature future espp offering period sixmonth espp purchase settle common stock espp previously authorize available pool share million share issue espp million total million share common stock reserve issuance espp million share available issuance espp december december million unrecognized compensation cost relate espp expect recognize estimate weightedaverage period year stockbase compensation follow table summarize stockbase compensation expense include consolidated statement income million year end december cost good sell research development expense sell general administrative expense stockbase compensation expense include total cost expense income tax effect stockbase compensation expense net tax capitalize stockbased compensation cost inventory total million million million capitalize stockbased compensation cost remain inventory million december million december million december stockbase compensation recognize expense requisite service period consolidate statement income straightline expense attribution approach stock option reduce estimate forfeiture estimate forfeiture base historical experience recognize tax benefit stockbase compensation apic incremental tax benefit realize tax attribute currently available utilize addition elect account indirect benefit stockbase compensation research tax credit extraterritorial income deduction consolidate statement income apic valuation assumption fair value option grant plan purchase espp estimate grant purchase date blackschole option valuation model blackschole option valuation model develop use estimate fair value trade option vest restriction fully transferable addition option valuation model require input highly subjective assumption include expect stock price volatility expect award life follow assumption calculate estimate fair value award year end december expect volatility stock option espp expect term year stock option espp riskfree interest rate stock option espp expect dividend yield fair value stock option grant calculate single option approach use blend historical volatility imply volatility trade option common stock determine expect volatility expect term stockbase award represent weightedaverage period award expect remain outstanding estimate weightedaverage expect term base historical cancellation historical exercise datum relate stock option contractual term vest term award riskfree interest rate base observe interest rate appropriate term stockbase award dividend yield base history expectation dividend payout defer compensation maintain retirement saving plan eligible employee defer compensation income tax purpose section k internal revenue code gilead science k plan certain foreign subsidiary maintain define benefit plan require local regulatory requirement total matching contribution expense gilead science k plan define benefit plan million million million maintain deferred compensation plan director key employee defer compensation amount defer participant deposit rabbi trust total asset liability associate defer compensation plan million december million december net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding period dilute net income share attributable gilead common stockholder calculate base weightedaverage number share common stock outstanding dilutive security outstanding period potential dilutive share common stock result assume exercise outstanding stock option psus assume exercise warrant relate convertible senior note include convertible senior note note note note collectively convertible note determine treasury stock method principal convertible note settle cash conversion spread relate outstanding convertible note include calculation dilute net income share attributable gilead common stockholder common stock result assume settlement conversion spread note dilutive effect average market price common stock period exceed conversion price common stock result assume settlement conversion spread note dilutive effect average market price common stock period exceed conversion price note note debt credit facility additional information include dilutive impact outstanding warrant relate convertible note period dilutive effect net income share calculation warrant relate note dilutive effect average market price common stock period exceed warrant exercise price warrant warrant dilutive effect average market price common stock period exceed warrant exercise price note debt credit facility additional information exclude stock option purchase approximately million weightedaverage share common stock outstanding million weightedaverage share computation dilute net income share attributable gilead common stockholder effect antidilutive follow table reconciliation numerator denominator calculation basic diluted net income share attributable gilead common stockholder million year end december net income attributable gilead share share calculation basic effect dilutive security stock option equivalent conversion spread relate convertible note warrant relate convertible note share share calculation dilute net income share attributable gilead common stockholder basic net income share attributable gilead common stockholder dilute segment information operating segment primarily focus discovery development commercialization innovative medicine area unmet medical need result operation report consolidated basis consistent internal management reporting review chief operating decision maker chief executive officer enterprisewide disclosure product sale revenue longlive assets geographic area revenue major customer present product sale product sale consist follow millions year end december antiviral product harvoni sovaldi truvada atripla stribild compleraeviplera viread genvoya antiviral total antiviral product product letairis ranexa ambisome zydelig total product sale revenue geographic region follow table summarize total revenue external customer collaboration partner geographic region million product sale productrelate contract revenue attribute region base shipto location royalty nonproduct relate contract revenue attribute region base location collaboration partner year end december revenues united states europe country total revenue longlive asset net book value property plant equipment office computer equipment united states billion december billion december corresponding international location million december million december individual international location account percent total balance revenue major customer follow table summarize revenue customer individually account total revenue percentage total revenue year end december mckesson corp amerisourcebergen corp cardinal health inc income taxis income provision income taxis consist follow millions year end december domestic foreign total income provision income taxis provision income taxis consist follow millions year end december federal current deferred state current defer foreign current defer provision income taxis cumulative unremitted foreign earning consider indefinitely reinveste foreign subsidiary taxis provide approximately billion december billion december residual tax liability amount remit approximately billion december billion december reconciliation federal statutory tax rate apply income taxis effective tax rate summarize follow year end december federal statutory rate state taxis net federal benefit foreign earning different rate research credit net unbenefitted stock compensation effective tax rate defer income taxis reflect net tax effect temporary difference carry amount asset liability financial reporting purpose amount income tax purpose significant component defer tax asset liability follow million december defer tax asset net operating loss carryforward stockbase compensation reserve accrual currently deductible defer revenue depreciation relate research credit carryforward net total defer tax asset valuation allowance valuation allowance total defer tax asset defer tax liability intangible unremitted foreign earning total defer tax liability net defer tax asset valuation allowance million december million december december likely realize benefit defer tax asset relate certain state net operating loss credit carryforward december federal net operating loss carryforward approximately million federal net operating loss carryforward start expire utilize federal tax credit carryforwards approximately million start expire utilize addition state net operating loss tax credit carryforward approximately million million respectively state net operating loss tax credit carryforward start expire utilize utilization net operating loss tax credit subject annual limitation ownership change limitation provide internal revenue code amend similar state provision annual limitation result expiration net operating loss credit utilization file federal state foreign income tax return jurisdiction unite states abroad federal income tax purpose statute limitation open onwards certain acquire entity statute limitation open year inception utilization net operating loss credit carry prior year california income tax purpose statute limitation open onwards income tax return subject audit federal state foreign tax authority currently examination irs tax year state foreign jurisdiction differ interpretation tax law regulation result significant dispute arise tax authority involve issue time deduction allocation income tax jurisdiction periodically evaluate exposure associate tax filing position total federal state foreign unrecognized tax benefit billion december million december total unrecognized tax benefit billion million december respectively recognize reduce effective tax rate period recognition continue classify interest penalty relate unrecognized tax benefit income tax provision consolidate statement income accrue interest penalty relate unrecognized tax benefit million december million december december believe reasonably possible unrecognized tax benefit decrease approximately million month expect clarification irs tax authority uncertain tax position respect remain unrecognized tax benefit currently unable reasonable estimate period cash settlement respective tax authority follow rollforward total gross unrecognized tax benefit liability millions december balance beginning period tax position relate current year addition reduction tax position relate prior year addition reduction settlement lapse statute limitation balance end period subsequent event enter license collaboration agreement galapagos nv galapagos clinicalstage biotechnology company base belgium development commercialization filgotinib jakselective inhibitor investigate inflammatory disease indication term agreement effective january upfront license fee payment million million equity investment galapago addition galapago eligible receive development regulatory milestonebase payment million salesbase milestone payment million tiere royalty global sale profit split potential copromotion territory select quarterly financial information unaudite follow amount million share amount st quarter nd quarter rd quarter th quarter total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute total revenue gross profit product sale net income net income attributable gilead net income share attributable gilead common stockholdersbasic net income share attributable gilead common stockholdersdilute gilead sciences inc schedule ii valuation qualifying account million balance additionscharged balance end beginning period expense deduction period year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset year end december account receivable allowance sale return allowance valuation allowance defer tax asset allowance doubtful account cash discount chargeback valuation allowance defer tax asset include million million december respectively relate acquisition item change disagreement accountant account financial disclosure applicable item control procedure evaluation disclosure control procedure evaluation december carry supervision participation management include chief executive officer chief financial officer effectiveness disclosure control procedure define rule ae securities exchange act amended exchange act control procedure company design ensure information require disclose company report file submit exchange act record process summarize report time period specify securities exchange commission rule form information accumulate communicate company management include chief executive officer chief financial officer appropriate allow timely decision require disclosure base evaluation chief executive officer chief financial officer conclude disclosure control procedure effective december b management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting term define rule af exchange act internal control system design provide reasonable assurance preparation fair presentation financial statement external purpose accordance generally accept accounting principle internal control system matter design inherent limitation provide reasonable assurance objective internal control system meet supervision participation management include chief executive officer chief financial officer conduct evaluation effectiveness internal control financial reporting base criterion establish committee sponsor organization treadway commission coso internal controlintegrate framework base evaluation conclude internal control financial reporting effective december independent register public accounting firm ernst young llp audit consolidated financial statement include annual report issue report internal control financial reporting december report audit internal control financial reporting appear c change internal control financial reporting management include chief executive officer chief financial officer evaluate change internal control financial reporting occur quarter end december conclude change quarter materially affect reasonably likely materially affect internal control financial reporting report independent register public accounting firm board director stockholder gilead sciences inc audit gilead sciences inc internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission framework coso criterion gilead sciences inc management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit conduct audit accordance standard public company accounting oversight board united states standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle company internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate opinion gilead sciences inc maintain material respect effective internal control financial reporting december base coso criterion audit accordance standard public company accounting oversight board united states consolidated financial statement gilead sciences inc report date february express unqualified opinion thereon ernst young llp redwood city california february item b information applicable iii item director executive officer corporate governance information require item concern director executive officer incorporate reference section definitive proxy statement file securities exchange commission pursuant regulation connection annual meeting stockholder proxy statement heading nominee board committee meeting executive officer section beneficial ownership reporting compliance write code ethic apply director employee include executive officer include limitation principal executive officer principal financial officer principal accounting officer controller person perform similar function code ethic available website httpwwwgileadcom investor section corporate governance change waiver code ethic disclose website intend satisfy disclosure requirement item form k amendment waiver provision code ethic disclose information website item executive compensation information require item incorporate reference section proxy statement heading executive compensation compensation committee interlock insider participation compensation committee report compensation nonemployee board member item security ownership certain beneficial owner management relate stockholder matter information require item incorporate reference section proxy statement heading security ownership certain beneficial owner management security authorize issuance equity compensation plan item certain relationship relate transaction director independence information require item incorporate reference section proxy statement heading nominee certain relationship relate party transaction item principal accountant fee service information require item incorporate reference section proxy statement head principal accountant fee service iv item